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Abstract

EVALUATION OF CANNABINOID RECEPTOR INTERACTION OF ANANDAMIDE,
AN ENDOGENOUS CANNABINOID RECEPTOR LIGAND
Irma Bateman Adams, Ph.D.
A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor
of Philosophy at Virginia Commonwealth University.
Virginia Commonwealth University, 1996
Director: Dr. Billy R. Martin, Professor
Department of Pharmacology and Toxicology

Recent evidence implicates anandamide as the endogenous ligand for the
cannabinoid receptor.

One purpose of this study was to determine the structural

requirements for anandamide's receptor interaction and the influence of
phenylmethylsulfonyl fluoride (PMSF), an enzyme inhibitor, on receptor affinity. A
second objective was evaluation of the correlation between affinities of the analogs and in

vivo pharmacological activities. The ability of anandamide and analogs to displace [3H]CP 55,940 was determined by a filtration assay. Displacement curves for anandamide in
the presence of PMSF produced a Ki of 89 ± 10 nM; without PMSF the Ki increased to
5400 ± 1600 nM. Anandamide analogs were evaluated for their ability to produce
antinociception and hypomotility. The levels of saturation and substituents for the
ethanolamide and hydroxyl groups of the anandamide structure were critical to receptor

xv
affinity and in vivo potency. Increasing the length of the N-substituent by one or two
carbons decreased receptor binding affinity. Methylations at carbons 2 and l' produced
compounds stable in the absence of PMSF. Addition of larger alkyl groups at these
positions or nitrogen methylation reduced receptor affinity and behavioral potency. These
results indicate that methylations at specific carbons of anandamide confer stability in vitro.
A final objective was to characterize anandamide's binding to the cannabinoid receptor in
the CNS. Anandamide's receptor binding affinities and binding densities, as determined
from autoradiographic experiments in rat brain, from selected brain areas were compared to
the receptor binding densities and patterns of two other compounds, CP 55,940 and SR
147116A, that bind to the central cannabinoid receptor. The lack of difference between
receptor affinity, receptor distribution and parallelism of the displacement curves indicate
that anandamide, SR 141716A and CP 55,940 are binding to the same receptor in the same
manner.

I.

General Introduction

Although used for centuries for both medicinal and recreational purposes, no other
drug of abuse, as defined by the United States Controlled Substances Act, arouses greater
controversy than cannabis. Cannabis use is widespread throughout the world; in fact, it is
the most prevalently used drug in many countries. Despite efforts to curtail its use in the
United States, cannabis remains one of the most commonly abused drugs, ranking only
behind the consumption of alcohol and cigarettes. According to the National Institute on
Drug Abuse 1995 National Household Survey on Drug Abuse, approximately 59% of
adults in the United States between the ages of 26 and 34 have used cannabis in their
lifetime. Importantly, 2-3% of the population in the United States consume cannabis on a
daily basis. Public debate centers upon the possible legalization of cannabis for certain
therapeutic uses, such as glaucoma treatment, appetite stimulation in AIDS patients and
suppressing nausea resulting from chemotherapy. By the early 1980s extensive research
had provided information concerning the identification of cannabinoids in the plant and the
physiochemical and biochemical properties of these compounds. Numerous breakthroughs
in the past few years have greatly increased our understanding of cannabinoids. The
history, chemistry, pharmacology and toxicology of cannabis in both animals and humans
is extensive. Furthermore, the complex and often ambiguous health consequences and
clinical utility of cannabinoids continue to be of vital concern to health care providers.
Recent advances, such as the characterization and cloning of a specific cannabinoid
receptor, identification of a second messenger system and isolation of an endogenous
ligand provide insight for the direction of future research for this fascinating dmg.
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History and Prevalence of Use
References to the use of the plant Cannabis sativa, also known as Indian hemp, date
back over twelve thousand years (Abel, 1979). Cannabis has long been used as a medicine
in China, India, the Middle East, South Africa and South America. Egyptian, Chinese
(2700 B.C.) and Assyrian (800 B.C.) sources indicate that it is one of the oldest drugs in
history (Mechoulam and Feigenbaum, 1987). The earliest reference to the medicinal
properties of cannabis dates back to 2700 B.C. (Grinspoon and Bakalar, 1993). The
Chinese emperor Shen-Nung described cannabis in a book that later became the standard
Chinese compendium of medicines. The Chinese used cannabis for treatment of
constipation, malaria, rheumatic pains and female disorders. The euphoric properties of
cannabis were discovered in India between 2000 and 1400 B.C., and cannabis was
recommended medicinally for reducing fevers, producing sleep, stimulating the appetite,
relieving headaches and curing venereal diseases (Mechoulam and Feigenbaum, 1987). In
addition to its purported medicinal properties, the ancient Chinese and Greeks used
cannabis to make ropes and clothes. Romans were also aware of the strength of cannabis
rope and used it in naval construction. The plant was cultivated for its fiber early in
American history at Jamestown, Virginia in 1611 (Grinspoon and Bakalar, 1993). Even
today, interest continues in the hemp plant for the purpose of making clothes.
Cannabis was introduced into Western medicine several millennia later following
the publication of a treatise in 1839 by W. B. O'Shaughnessy, a 30-year-old Irish
physician serving in the British army in India (Lemberger, 1984; Snyder, 1971). He
carefully reviewed literature on the uses of cannabis in Indian medicine that spanned nine
hundred years and concluded that cannabis was a very safe drug. To further confirm the
safety of cannabis, he conducted a series of experiments in animals to determine its effects
and dosage limits (Snyder, 1971). He found that cannabis was not harmful in animals, and
even high doses did not kill mice, rats or rabbits. He administered cannabis to patients
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suffering from seizures, tetanus, rabies and rheumatism and recorded success, though sideeffects, such as total catalepsy, sometimes occurred. He noted the anticonvulsive,
analgesic, antianxiety and antiemetic properties of the drug. The reports of O'Shaughnessy
made cannabis an acceptable form of medicine in England and other European countries
(Mechoulam and Feigenbaum, 1987). At the turn of the twentieth century, the medicinal
use of cannabis waned in the United States and Europe due to the development of synthetic
medicines.
The rising fear of cannabis use in the United States began in the 1920s, and the use
of cannabis was abolished in the United States in 1937 with the enaction of the Marijuana
Tax Act (Musto, 1987). The Mexican term marijuana refers to cannabis leaves or other
crude plant material. Despite legal measures in the United States, cannabis still became a
major drug of abuse in the late 1960s, with peak usage occurring in the late 1970s and early
1980s. A United States Bureau of Census report in 1971 indicated that 40% of individuals
between 18-25 years of age had experimented with cannabis, and 18% from the same age
group currently used the drug. Drug usage data was also obtained in the United States with
the National Household Survey on Drug Abuse and the Monitoring the Future Survey,
which began collecting information in 1975 from young adults, college age students,
twelfth grade students in public and private schools. Eighth and tenth graders were added
in 1991. According to the Monitoring the Future Survey, 1979 was the peak year of use
with 60.4% of twelfth graders having tried cannabis in their lifetime, and 50.8% of high
school seniors in 1979 had used cannabis in the past year. In 1978, 37.1% of twelfth
graders surveyed had used cannabis within 30 days, and 10.7% used cannabis on a daily
basis. Following these peak years, cannabis use began a slow, but continuous decline,
with the lowest levels of annual use occurring in 1992. In 1992, 21.9% of twelfth graders
had used cannabis in the past twelve months, and 1.9% used the drug on a daily basis.
The decline in use was linked to an increase in perceived risk and personal disapproval of
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drugs (Hall, Johnston and Donnelly, in press). Surveys since 1992 indicated significant
increases in all use categories (Johnston, O'Malley and Bachman, 1995). From 1992 to
1994, lifetime use in twelfth graders increased 5.6%; annual use increased 8.8%; 30-day
use increased 7.1%, and daily use increased 1.7%. Although the current levels of cannabis
use in the United States are still much lower than the peak periods, the recent increases
represent an early warning that cannabis popularity could continue to increase, especially
with the high school population. The recent upturn has been attributed to a decline in social
disapproval of cannabis and in perceived risk, lower public attention to cannabis and an
increase in prodrug messages in popular culture (Hall, Johnston and Donnelly, in press).
The 1994 Monitoring the Future Survey reports that "perceived harmfulness" of cannabis
experimentation for all age groups decreased. When asked in 1994 if "great risk" would
result if cannabis was "smoked regularly", 65% of twelfth graders reported affirmatively.
This response represents a 7.5% decrease from 1993. There was also an increase in
participants who found that obtaining cannabis was "fairly or very easy." The increases in
cannabis use, decline of perceived harmfulness and decline in social disapproval
demonstrate an erosion of the anti-drug attitude in the United States (Hall, Johnston and
Donnelly, in press).
Epidemiological evidence is also available from other countries, and these studies
are reviewed by Hall et al. (in press). In Canada several school studies have shown similar
trends to the United States, with a rise in use in the 1970s followed by a decline throughout
the 1980s. However, the rates of illicit drug use were lower than in the United States. A
national telephone survey reported that 23% of those sampled had ever tried cannabis (Hall,
Johnston and Donnelly, in press). Cannabis is the most commonly used illicit drug in
Australia. A 1993 national survey of adults demonstrated that one-third had tried cannabis.
Large increases in use between 1988 and 1992, especially in males, were reported in the
Netherlands from a national survey of students aged 10 to 18.
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Although cannabis is used throughout the world, limited survey data are available in
other parts of the world. Often these data provides only a crude indication of use. Survey
methods are not reported, results are presented in a summary format and the levels of use
of teenagers is often underreported. Nevertheless, these surveys do give an indication of
overall levels of use. Limited data are available from Africa (Hall, Johnston and Donnelly,
in press). A survey of 5000 workers reported a prevalence of 11.5% for having used
cannabis. In a Moroccan survey from Tangier, two-thirds of 500 students reported trying
cannabis. Reported rates of cannabis use in South American countries is lower than in
Western countries, including the United States, Canada, Europe and Australia (Hall,
Johnston and Donnelly, in press). In Brazil, two school-based surveys conducted in 1987
and 1989 demonstrated that 2.9% in 1987 and 3.4% in 1989 had used cannabis. Similar
results were found in a 1992 National Household Survey on Drug Abuse in Colombia.
Among 18- to 24-year-olds, 1.5% had used cannabis in the past year. In a survey
conducted in Athens, Greece, which was based upon the substance use and attitudes
sections of similar questionnaires of the World Health Organization and the United
Nations, cannabis or hashish was the most frequently used illicit drug (Kokkevi, 1994).
The highest lifetime rate of cannabis use was found in 25- to 35-year-old males (27.9%).
A compilation of limited studies conducted in various hospitals in Lebanon indicated that
hashish smoking is common, especially in rural areas where it often used daily (Hachem,
1994). One street study found 142 out of 198 participants were hashish users (Hachem,
1994). In Mexico, cannabis has been the most reported illicit drug of initiation in the past
three years (Tapia-Conyer et al., 1994). India has a long tradition of cannabis use
associated with religious ceremonies. Yet, only very limited surveys are available.
Surveys conducted in three Northern Indian states between 1989 and 1991 found a lifetime
prevalence rate of 3% and current use rate of 1% (Hall, Johnston and Donnelly, in press).
In Southern India a lifetime prevalence rate of 7% has been reported. Higher prevalence
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rates of 10% to 27% exist among students. The limited data on cannabis use in African,
Asian, Central and South American and Middle Eastern countries suggest that these
countries have lower rates of lifetime cannabis exposure than many Western countries.
Before definite conclusions are drawn, more complete and standardized surveys need to be
conducted. However, it is clear that cannabis is used throughout the world, albeit at
varying degrees.

The Cannabis Plant
The flowering tops and leaves of the plant Cannabis sativa, subspecies indica,
secrete a resin containing psychoactive compounds called cannabinoids. The highest
concentration of cannabinoids in the plant is found in the flowering tops followed by the
leaves. Small amounts of cannabinoids are found in the stem and roots, and none in the
seeds. The cannabinoid content of the plant varies widely depending upon the climate,
soil, cultivation and type of plant. The plant is cut, dried and incorporated into cigarettes
with or without tobacco. Three types of plant preparations are used, as identified by the
Indian names bhang, ganja and charas (Grinspoon and Bakalar, 1993). Bhang is made
from dried leaves and tops of uncultivated plants and contains a low resin content. Ganja is
obtained from the leaves and tops of cultivated plants and has a higher resin content. The
first two preparations are referred to as marijuana. Charas, also known as hashish, is
prepared from the resin itself and is 5 to 10 times more potent than marijuana. Plant
products are also chewed, smoked in a waterpipe or eaten in baked goods.
A concern exists that the problem of elevated cannabis use may be compounded by
recent increasing concentrations of �9 -tetrahydrocannabinol (�9 -THC), the primary
psychoactive constituent in the plant, found in confiscated cannabis. During the late 1960s,
the average level of �9-THC content was 1.5%. The levels steadily increased to the early
1980s when concentrations had doubled to 3.0-3.5% (ElSohly and Ross, 1994). Seized

7
samples composed primarily of buds and sinsemilla (unfertilized flowering tops from the
female Cannabis plant) contain much higher concentrations of t,9-THC. In fact, samples of
cannabis sometimes contain concentrations of t,9-THC as high as 20%. Emphasis upon
genetic experimentation and cross-breeding in recent years and developments in indoor
hydroponic cultivation techniques have contributed to higher THC content in cannabis
plants (Clarke, 1981).

These efforts have enhanced THC levels in Dutch hemp

("Netherweed") to concentrations averaging 20% (Hall, Johnston and Donnelly, in press).
One may argue that the elevation in levels of t,9-THC has not contributed to cannabis use
since there was a decline in use during the time when levels had increased and then
stabilized. On the other hand, if highly potent cannabis becomes readily available, the
patterns in cannabis use could be affected.

Chemistry
The cannabis plant contains over 400 chemical compounds. Approximately 60 of
these compounds are cannabinoids. The term cannabinoid refers to the C2 l -compounds
present in the plant and includes their transformation products and related analogs. The
elucidation of the principal psychoactive constituents facilitated the ease of studying the
pharmacological and behavioral effects of cannabis' specific constituents. Marijuana
contains over 60 compounds which are structurally related cannabinoids. Four compounds
important in terms of cannabinoid pharmacology are cannabinol (CBN), cannabidiol
(CBD), (-)-t.9-trans-tetrahydrocannabinol (t.9-THC) and t,8-THC (Figure 1). Cannabinol
was the first cannabinoid to be isolated and purified (Wood, Spivey and Easterfield, 1899),
but its structure was not determined until later (Adams, Baker and Wearn, 1940). Also,
cannabidiol was isolated and purified (Adams, Hunt and Clark, 1940), and its structure
was later identified (Mechoulam and Shvo, 1963). The isolation of cannabinol and
cannabidiol in the 1940s provided the general structure of the active principle of cannabis,
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Cannabinol

Cannabidiol

Figure 1. Structures of naturally occurring cannabinoids.
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but CBN had little and CBD had no psychotomimetic activity (Adams, Baker and Wearn,
1940; Adams, Hunt and Clark, 1940). Mechoulam and his colleagues in the 1960s first
isolated �9 -THC, later found primarily responsible for the psychoactive properties of the
plant

(Gaoni and Mechoulam, 1964). The synthesis of racemic (±)-�9 -THC was

described in 1965 (Mechoulam and Gaoni, 1965). A second psychotomimetic compound
was also identified as � 8 -THC, a positional isomer of �9 -THC (Hively, Mosher and
Hoffmann, 1966). The pharmacological profiles for the two components are similar, with
�9 -THC possessing somewhat greater potency.
Two numbering systems exist for cannabinoids:

the dibenzopyran and

monoterpenoid numbering systems. The former is recognized in Chemical Abstracts and
will be used when referring to both naturally occurring and synthetic cannabinoids (Figure
2). The formation of salts of naturally occurring cannabinoids is not possible since these
compounds lack either a basic or acidic functional group. As a result, �9 -THC is a
noncrystalline, waxy-liquid substance at room temperature. �9-THC is unstable and loses
potency upon storage. The main decomposition product of �9 -THC is CBN. The high
degree of lipophilicity and instability of cannabinoids complicates the preparing and
handling of cannabinoid solutions.

Structure-Activity Relationship Studies of Cannabinoids
Efforts were undertaken to synthesize and evaluate cannabinoid analogs for the
purpose of separating desired pharmacological effects from adverse effects and for the
elucidation of the biochemical and molecular mechanisms of cannabinoid action. Initially,
due to the lipophilic nature of �9 -THC and the central depressant effects, cannabinoids
were thought to mediate their actions through disruption of membrane ordering, similar to
the mechanism of action of general anesthetics (Lawrence and Gill, 1975; Paton and
Pertwee, 1972). Extensive structure-activity relationship (SAR) studies of cannabinoid
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8
7

5'

Dibenzopyran numbering

7

6

5"

Monoterpene numbering

Figure 2. Cannabinoid numbering systems.
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OH

OH

dimethylheptyl
ll-OH-L19 -THC-dimethylheptyl

CP 55,940

OH

OH
CP 55,244

WIN 55,212

Figure 3. Structures of ll-OH-L19-THC-DMH, CP 55,940, CP 55,244 and WIN 55,212.
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analogs revealed strict structural requirements for pharmacological activity and provided
early evidence for a specific cannabinoid receptor. The first systematic SAR study in
cannabinoids was conducted by Adams (1942) in the 1940s, and this work has been
substantially supplemented with the pharmacological characterization of a wide variety of
natural and synthetic cannabinoids, as reviewed by Razdan (1986). SAR studies are based
primarily on animal behavioral paradigms such as dog static ataxia, drug discrimination and
other specific mouse tests. While correlation does exist between potency in the dog static
ataxia test and the psychoactive component of cannabinoids in humans (Razdan, 1986),
extrapolation from animal models to human marijuana intoxication is still problematic.
However, Balster and Prescott (1992) did describe a good correlation between human data
and drug discrimination in animals for approximately 20 cannabinoid compounds.
Chemically distinct subclasses of cannabinoid analogs exist with greater potency
than t19 -THC. Potent compounds have resulted from numerous structural alterations made
to the basic template of t19 -THC. Changes in side chain length or branching of the side
chain at the C l' or C2' position (Figure 2) dramatically affects potency. Substitution of the
pentyl group with a dimethylheptyl side chain and hydroxylation at carbon 11 of t18 -THC
resulted in 11-0H-!18 -THC-DMH, a compound several hundred times more potent than t18 THC in behavioral assays (Little et al., 1989; Mechoulam et al., 1988). A corresponding
pharmacologically potent derivative of t19 -THC, 11-0H-!19 -THC-DMH (Figure 3), was
also developed (Martin et al., 1991; Razdan, 1987). Hydroxylation in the side chain of t19 THC or t18 -THC at C3' increased behavioral activity 2 -fold (Agurell et al., 1976 ; Handrick
et al., 1982). Hydroxylation at the CS' position of t1 8 -THC had little effect upon
behavioral activity; yet, hydroxylation at the C l' and C2' positions decreased activity
(Agurell et al., 197 6). These studies suggest that the position of side chain substituents
and the orientation of the side chain are important for cannabinoid activity. Unsaturation in

13
the side chain did not affect potency, even though unsaturation acts to restrict the
orientation of the side chain.
�9-THC possesses a phenolic hydroxyl, gem-dimethyl groups on the pyran ring
and an oxygen in the pyran ring. Alterations have been made to these sites (Razdan,
1986).

Substitution of the pyran oxygen with nitrogen or carbon atoms did not

dramatically affect potency. Optimal activity resulted when the phenol group was either
free or esterified. Etherification of the phenolic hydroxyl of �8- and �9-THC to 0-methyl
analogs eliminated activity. Removal of gem-dimethyl groups on the pyran ring decreased
activity. Alterations in the location and number of unsaturations in the terpene ring of �9THC produced differing effects in potency. Optimal activity resulted with a double bond at
the C9 position, as in �9-THC; potency was somewhat reduced in �8-THC, and potency
was even further reduced with �6a-10a_THC and CBN, which has complete unsaturation.
Synthesis of the dimethylheptyl derivatives was based upon the three-point
attachment theory and the necessity of an intact dibenzopyran ring system. A minimum of
three points of attachment of �9-THC were postulated to interact with a receptor: 1) a free
phenolic hydroxyl group; 2) an appropriate substituent at the C9 position; and 3) a
lipophilic side chain (Binder et al., 1984; Howlett et al., 1988). While attempting to
develop a unique analgesic, a group at Pfizer prepared novel bicyclic cannabinoid analogs
with pharmacological profiles similar to �9-THC (Melvin et al., 1984). They found that
the benzopyran ring system can be extensively modified or removed without loss of activity
(Johnson and Melvin, 1986). CP 55,940 (Figure 3), the most widely used compound in
the series, possessed potency 4-25 times greater than �9 -THC, depending upon the
pharmacological assay. Since the synthetic cannabinoids lacking a benzopyran ring
represented the first significant deviation from the traditional THC structure, they were
referred to as nonclassical cannabinoids. Due to the divergence in structure, great attention
was placed upon proving that the bicyclic analogs were definitely THC-like. Evidence that
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CP 55,940 is a cannabinoid emerged from studies showing that CP 55,940 and �9 -THC
cross-generalized in rat and monkey drug discrimination, and cross tolerance developed
between the two compounds (Gold et al., 1992; Pertwee, Stevenson and Griffin, 1993).
The pharmacological activity of �9-THC is stereoselective, with the (-)-trans isomer
having 6-100 times more potency than the (+)-trans isomer, depending upon the
pharmacological test (Dewey, Martin and May, 1984). However, the pharmacological
profiles for the two enantiomers are similar. It has been argued that lack of complete
enantioselecti vity is due to contamination of the (+)-isomer with the (-)-isomer
(Mechoulam, 1988). Indeed, synthesis of crystalline derivatives of THC resulted in much
greater purity of enantiomers and enantioselectivity (Little et al., 1987). Stereoselectivity
for the psychoactive properties of cannabinoids was also demonstrated in human studies.
The use of highly pure enantiomers of 11-0H-�8-THC-DMH further established that
cannabinoids exhibit enantioselectivity (Mechoulam et al., 1988). The nonclassical tricyclic
compounds CP 55,244 [(-)-ACD] (Figure 3) and CP 55,243 [(+)-ACD] showed
enantioselectivity; CP 55,244 was significantly more potent than CP 55,243 in several of
the behavioral tests (Little et al., 1988). The existence of high enantioselectivity reinforced
the notion that cannabinoids act through a specific receptor. Although progress in the
development of potent cannabinoid agonists has been slower than for other centrally acting
agents, potent agonists recently have emerged and contribute not only to SAR, but to the
notion that a highly unique endogenous cannabinoid exists.
Although the bicyclic analogs contained unique characteristics, molecular modeling
studies revealed that they still retained most of the structural characteristics of �9-THC.
However, a truly novel class of compounds has emerged that differs greatly from both
classical and bicyclic cannabinoids. Pravadoline, a non-steroidal antiinflammatory agent,
had analgesic properties, but interestingly did not interact with the opioid system or inhibit
cyclooxygenase.

The search for the compound's mechanism of action led to the
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development of aminoalkylindoles, such as WIN 55,212 (Figure 3) (Ward et al., 1990;
Ward, ChjJders and Pacheco, 1989). These compounds, though structurally quite distinct
from other cannabinoids, competed for binding to the cannabinoid receptor (Pacheco et al.,
1991) and possessed cannabimjmetic properties, including antinociception, in mjce and rats
(Compton et al., 1992a). The discovery of anandamjde (arachidonylethanolamide) as a
proposed endogenous cannabinoid ligand added yet another novel class to the cannabinoid
pharmacophore of compounds that produce effects simjJar to !i9-THC (Figure 4) (Devane
et al., 1992). Confirming the similarity of anandamide with Li9-THC requires future
testing, particularly in humans. The emergence of four chemically distinct classes of
cannabinoids will provide probes for studying the diverse actions of cannabinoids, and
these probes should facilitate the separation of the psychoactive properties from the
pharmacological effects.

Animal Models and Pharmacology
The purpose of evaluating cannabinoids in animals is to establish a parallel
relationship between animals and humans and to extrapolate the animal effects to humans.
The development of a number of animal models in the mouse, rat, dog, rabbit and monkey
have allowed researchers to predict the psychoactivity of novel compounds. Extensive
reviews of these results are found elsewhere (Dewey, 1986; Razdan, 1986).
Pharmacological effects have been measured with models such as dog ataxia (Loewe,
1947), the THC-seizure susceptible rabbit (Consroe, Martin and Fish, 1982), monkey
overt behavior (Edery et al., 1971; Edery et al., 1972; Grnnfeld and Edery, 1969), drug
discrimjnation (Balster and Prescott, 1992) and a mouse behavioral battery consisting of
spontaneous locomotor activity, hypothermja, immobility (catalepsy) and antinociception
(Martin, 1985). Although cannabinoids have direct cellular actions on peripheral tissues,
most of the behavioral and pharmacological effects studied by researchers appear to involve
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the central nervous system (Dewey, 1986). The high lipophilicity of cannabinoids allows
passage across the blood-brain-barrier.
Cannabinoids produce a unique syndrome of effects on the behavior of a wide
variety of animal species. These behavioral effects are characterized at low doses as a
mixture of depressant and stimulatory effects and at higher doses as predominantly CNS
depression (Dewey, 1986). The depressant effects of psychotomimetic cannabinoids differ
from other CNS depressants. ,19 -THC and other psychoactive cannabinoids in mice
produce a "popcorn" effect. Groups of mice in an apparently sedate state will jump
(hyperreflexia) in response to auditory or tactile stimuli. As animals fall onto other
animals, they resemble corn popping in a popcorn machine. This state of hyperreflexia is
observed during the depressant stage at higher doses (Dewey, 1986). Cannabinoids
generally cause a reduction in spontaneous locomotor activity (Little et al., 1988) and a
decrease in response rates with different reinforcement schedules (Carney et al., 1979;
Zuardi and Karniol, 1983).
With the drug discrimination model, animals use internal cues to discriminate
between the subjective effects of different drug classes. In this paradigm, rats, pigeons or
non-human primates are trained to make different responses for reinforcement contingent
upon administration of either the training drug or vehicle (Gold et al., 1992; Jarbe and
Hiltunen, 1987; Weissman, 1978). After successful discrimination training, other drugs
may be administered to see if they produce similar stimulus characteristics as the training
drug. A correlation exists between drugs that generalize to ,19 -THC and bind to the central
cannabinoid receptor.

The bicyclic compounds (Gold et al., 1992) and the

aminoalkylindoles (Compton et al., 1992b) substitute for ,19 -THC, whereas drugs from
other classes do not (Balster and Prescott, 1992). Ultimately, the best model for evaluating
a drug's reinforcing effects and predicting abuse liability is a drug self-administration
paradigm. Animals do not readily self-administer ,19-THC (Harris, Waters and McLendon,
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1974), and CP 55,940 does not maintain intravenous self-administration with a fixedinterval schedule in rhesus monkeys (Mansbach etal., 1994). The lack of reinforcing
effects of cannabis is consistent with the mild dependence properties in humans. On the
other hand, it is possible that animals will self-administer cannabinoids once appropriate
models are discovered.
Cannabinoids also impair learning and memory in rodents (Carlini etal., 1970) and
non-human primates (Ferraro and Grilly, 1973). In rats, the delayed match to sample
memory task (Heyser, Hampson and Deadwyler, 1993), Lashley III maze (Carlini etal.,
1970) and the eight arm radial-maze (Nakamura et al., 1991) were used to measure
memory disruption by cannabinoids. State-dependent learning studies have been used to
examine the influences of drugs upon the process of conditioning, or memory formation
and retrieval. State-dependent learning occurs when an association learned in one condition
is more easily retrieved in that same condition. This paradigm has been useful for
determining some of the disruptive effects of fl9-THC on memory and performance. The
effects of fl9-THC upon state-dependent learning have been reported in tasks involving
avoidance learning and conditioned suppression (farbe and Mathis, 1992). Tolerance does
develop to the disruptive and subjective drug-state effects of fl9-THC (farbe, 1978; farbe
and Mathis, 1992).
The high numbers of cannabinoid receptors in the hippocampus may mediate the
disruption in cognition (Herkenham etal., 1991c; Jansen etal., 1992; Thomas, Wei and
Martin, 1992). Intrahippocampal administration of CP 55,940 produced a dose-dependent
increase in the number of errors in the eight arm radial-maze test without elicitation of other
pharmacological effects (Margulies and Hammer, 1991). Another study showed that the
disruption in the delayed match to sample memory task induced by acute administration of
fl9-THC was similar to that produced by damage to the hippocampus (Heyser, Hampson
and Deadwyler, 1993). This disruption was associated with a specific decrease in
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hippocampal cell discharge only during the encoding phase of the task; the effects were
reversible within 24 hours of dosing. A number of other studies have examined the effects
of cannabinoids on hippocampal ultrastructure, and are reviewed by Solowij (in press-a).
While 119 -THC, CP 55,940 and WIN 55,212-2 all impaired working memory in rats,
anandamide failed to do so in either the eight arm radial-maze or the delayed nonmatching
to sample memory task (Crawley et al., 1993). Lichtman et al. (1995) also found that CP
55,940, 119-THC and WIN 55,212-2 administered systemically impaired spatial memory in
rats, as assessed by the eight arm radial-maze, and retarded completion time; neither
anandamide nor cannabidiol affected memory. Intrahippocampal administration of CP
55,940 impaired memory, but did not inhibit completion time. The intrahippocampal
effects of CP 55,940 appeared specific to cognition since no other pharmacological effects
were produced. The inability of anandamide to disrupt memory in rats illustrates a possible
difference between the endogenous ligand and other cannabinoids and underscores the
importance of further comparisons (Crawley et al., 1993; Lichtman, Dimen and Martin,
1995). In a series of chronic studies, rhesus monkeys were trained for one year to perform
operant tasks before one year of chronic cannabis administration (Slikker et al., 1992).
Task performance was impaired for over a week after cessation of use, but performance
returned to baseline levels three weeks after cessation. The effects of chronic exposure
were reversible with no apparent long term behavioral effects.

Mechanism of Action
Cannabinoids produce a myriad of pharmacological and behavioral effects which
most likely involve numerous neural substrates that traverse the entire brain. The
complexity of the pharmacological effects produced by cannabinoids is reflected in the
above discussion on animal models. The most likely candidate for mediating the central
effects of cannabinoids is a receptor mechanism. Discerning the mechanism of action for
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cannabinoids transpired over several decades, and many difficulties encumbered the
progress.

Enantioselectivity provided initial evidence of receptor involvement, as

discussed earlier. The high degrees of enantioselectivity in several of these analogs indicate
a very specific mechanism of action, such as that involving a receptor. The lack of an
appropriate radiolabeled ligand greatly hindered proving that cannabinoids exerted their
interactions through a specific central receptor. Early attempts to identify a receptor in
crude rat brain membranes by a ligand binding assay using [3H]-�8-THC failed (Harris,
Carchman and Martin, 1978). Saturable binding did not result, and only 10% displaceable
binding could be achieved. However, these investigators found displaceable binding in
hepatocytes, which suggested that assessing receptor binding was feasible.
The synthesis and radiolabeling of the potent bicyclic cannabinoid CP 55,940
allowed identification of a receptor in rat brain membranes (Devane et al., 1988). Analysis
of the data revealed a single binding site that possessed saturable and reversible high
affinity binding. Other labeled cannabinoids, such as the dimethylheptyl (DMH) derivative
of [3H]-l l-OH-�9-THC (Thomas, Wei and Martin, 1992) and [3H]-WIN 55,212-2
(Compton et al., 1992a; Haycock et al., 1991), also bind to this receptor. This receptor
displays selectivity for cannabinoids, as other classes of centrally acting compounds do not
compete for cannabinoid binding (Howlett, Evans and Houston, 1992). Pharmacological
potency of cannabinoids correlates well with their affinity for the cannabinoid binding site
(Compton et al., 1993). In addition, binding affinities correlated with in vivo potency in
the rat drug discrimination model and psychotomimetic activity in humans (Balster and
Prescott, 1992). These findings suggest that this receptor mediates most of the central
cannabinoid effects across several different animal species.
According to autoradiographic studies, the distribution of the cannabinoid receptor
is heterogeneous in several mammalian species, conserved and neuronally located
(Herkenham et al., 1990; Herkenham et al., 1991b; Herkenham et al., 1991c). The

20
densest binding occurs in the basal ganglia (substantia nigra pars reticulata, globus
pallidus, entopeduncular nucleus and lateral caudate putamen), and the molecular layer of
the cerebellum. Binding in these regions may explain cannabinoid interference with
movement. Intermediate levels of binding were found in the CA pyramidal cell layers of
the hippocampus, the dentate gyrus and layers I and VI of the cortex. ,:i9-THC disrupts
short-term memory in humans (Chait and Pierri, 1992). Thus, cannabinoid effects on
memory and cognition are consistent with receptor localization in the hippocampus and
cortex. The hippocampus stores memory and codes sensory information. The presence of
cannabinoid receptors in regions associated with mediating brain reward (ventromedial
striatum and nucleus accumbens) suggests an association with dopamine neurons. Sparse
levels were detected in the brainstem, hypothalamus, corpus callosum and the deep
cerebellum nuclei. Low levels of receptors in brainstem areas controlling cardiovascular
and respiratory functions is also consistent with the low of lethality of cannabis. Other
ligands, such as [3H]-WIN 55,212 (Jansen et al., 1992) and [3H]-l l-OH-Li9-THC-DMH
(Thomas, Wei and Martin, 1992), generated similar localization patterns. Binding has also
been found in the peripheral B lymphocyte-enriched areas including the marginal zone of
the spleen, nodular corona of Peyer's patches and the cortex of the lymph nodes (Lynn and
Herkenham, 1994).
Prior to the characterization of a receptor, data demonstrated that cannabinoids
inhibited adenylyl cyclase by probable interaction with an inhibitory G protein (Gi)
(Howlett and Fleming, 1984). Researchers proposed that a cannabinoid receptor was
linked to a Gi protein which, when activated, inhibited the activity of adenylyl cyclase.
Adenylyl cyclase then cannot catalyze the conversion of ATP to the second messenger
cyclic AMP (cAMP). The inhibition of adenylyl cyclase by cannabinoids took place in
neuroblastoma cell membranes, rat brain slice membranes and cultured cerebellar neurons
(Bidaut-Russell, Devane and Howlett, 1990; Howlett, Qualy and Khachatrian, 1986;
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Pacheco, Ward and Childers, 1993). While extensive in vitro evidence exists for a
cannabinoid receptor/adenylyl cyclase interaction, determining a pharmacological effect
produced by adenylyl cyclase inhibition is difficult. Recently, Welch et al. (1995)
demonstrated that pertussis toxin blocked the antinociceptive properties of cannabinoids in
mice. Pertussis toxin prevents Gi proteins from interacting with receptors. This work
suggests that the analgesic properties of cannabinoids might be due to cannabinoid receptor
activation of a Gi protein. Furthermore, forskolin, which stimulates adenylyl cyclase,
thereby producing increased levels of cAMP, and chloro-cAMP, a stable analog of cAMP,
decreased cannabinoid-induced antinociception. Thus, both preventing Gi proteins from
interacting with cannabinoid receptors and increasing the levels of cAMP interfered with the
production of antinociception (Welch, Thomas and Patrick, 1995). These data suggest
involvement of adenylyl cyclase in the antinociception of cannabinoids.
Definitive evidence for a specific cannabinoid receptor became apparent when it was
cloned (Matsuda et al., 1990). A clone isolated from a rat brain library had homology with
other receptors that interacted with G proteins in the cell membrane. Yet, none of the
traditional agonists of G proteins bound to this receptor clone.

An identification

breakthrough occurred with the discovery that the mRNA distribution of the receptor clone
paralleled that of the cannabinoid receptor. Confirmation of the identity of the clone
occurred when adenylyl cyclase was inhibited upon exposure to CP 55,940 and �9-THC in
cells transfected with this clone. Adenylyl cyclase in non-transfected cells did not respond
to cannabinoids. The human cannabinoid receptor was subsequently cloned and found to
have almost identical homology to the rat receptor (Gerard et al., 1991). The cannabinoid
receptor, abbreviated as CB I, belongs to a G protein-coupled receptor sub-family which
includes the adrenocorticotropin and melanotropin receptors (Mountjoy et al., 1992). An
amino-terminal variant, designated CB I A , of CB I has been discovered in brain and several
peripheral tissues (Shire et al., 1995). CB I A results from alternative splicing of CB 1
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resulting in deletion of 60 amino acid residues in the amino terminus. Recently, a distinct
peripheral cannabinoid receptor, designated CB2, was identified in macrophages in the
marginal zone of the spleen (Munro, Thomas and Abu-Shaar, 1993). Although CB I and
CB2 share only approximately 40% homology, �9 -THC and CP 55,940 demonstrate
similar binding affinity for both receptor subtypes. The cloning of a peripheral receptor is
consistent with previous data showing cannabinoid binding to mouse spleen cells
(Kaminski et al., 1992) and to the rat immune system (Lynn and Herkenham, 1994 ). CB 1
RNA transcripts have been identified in mouse spleen cells (Kaminski et al., 1992) and
human peripheral blood lymphocytes (Bouaboula et al., 1993); CB2 RNA transcripts are
expressed in the rat spleen (Munro, Thomas and Abu-Shaar, 1993). The role of this
receptor in the spleen remains unknown. Slipetz et al. (1995) demonstrated that the human
peripheral receptor (CB2) is functionally coupled to inhibition of adenylyl cyclase activity
by a pertussis toxin-sensitive G-protein. A comparison of the pharmacology and signal
transduction of the human CB I and CB2 receptors indicate that both receptor subtypes
display similar pharmacological and biochemical properties, except CB2 did not couple to
the modulation of Q-type calcium channels or inwardly rectifying potassium channels
(Felder et al., 1995). The discovery of a second receptor raises the possibility that other
receptors with unique functional roles may exist.
Cannabinoids also produce effects through second messenger systems other than
adenylyl cyclase. Initial evidence implicating calcium came from a study in which �9-THC
inhibited calcium uptake following depolarization in mouse brain synaptosomes (Harris and
Stokes, 1982). Electrophysiological studies showed that cannabinoids inhibited an omega
conotoxin-sensitive, high voltage-activated N-type calcium channel (Caulfield and Brown,
1992; Mackie and Hille, 1992). The inhibition of calcium channel activity was pertussis
toxin-sensitive and stereospecific, suggesting a receptor-mediated process. In contrast,
other data demonstrated that calcium influx in non-transfected cells occurred through a non-
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receptor process (Felder et al., 1992). However, high concentrations of cannabinoids were
used, and calcium influx was also observed in non-transfected cells. Cannabinoids have
also been reported to mediate an enhancement of A-type potassium channels in cultured
hippocampal neurons through the cannabinoid receptor (Deadwyler et al., 1993).
Several recent studies have explored the biological functions and gene regulation
associated with the cannabinoid receptor. Bouaboula et al. (1995) discovered that CP
55,940, in addition to the inhibition of cAMP accumulation, induces the expression of the
immediate-early growth-related gene Krox-24 in astrocytoma cells. The transduction
pathway between the cannabinoid receptor and Krox-24 involves a pertussis toxin-sensitive
GTP-binding protein and is independent of cAMP metabolism (Bouaboula et al., 1995a).
Krox-24 induction was inhibited by the tyrosine kinase inhibitor herbimycin A, suggesting
that a protein kinase may lie on the route between Gi and Krox 24. The authors concluded
that one receptor subtype (CB1) may be coupled to two separate effector systems. The
precise role of the cannabinoid receptor in astrocyte cells remains under investigation. In
another study, cannabinoids induced phosphorylation and activation of mitogen-activated
kinases (MAP) in CHO cells transfected with the human CB I receptor (Bouaboula et al.,
1995b). The signal transduction between CB1 and MAP kinases involves a pertussis
toxin-sensitive GTP-binding protein and is independent of cAMP metabolism. The
coupling of CB I and mitogenic signal pathway may explain the mechanism of action
underlying cannabinoid-induced Krox-24 induction. Thus, activation of MAP kinase may
be a candidate for regulation of Krox-24 induction. Das et al. (1995) found that a
cannabinoid receptor-mediated signaling pathway is present in the mouse uterus, and this
organ has the capacity to synthesize anandarnide. THC rapidly and transiently upregulated
the gene encoding lactoferrin. Lactoferrin is an iron-binding glycoprotein proposed to be
involved in immunomodulation and growth promotion.

The authors propose that
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pregnancy failures and fetal losses that have been reported with exposure to cannabinoids
may be mediated via interactions with uterine cannabinoid receptors (Das et al., 1995).
Other systems have been proposed for the signal transduction of cannabinoid
receptor activation, though the evidence is not as compelling. Some data suggest that
cannabinoids might activate the inositol phospholipid pathway. In this signaling pathway,
a receptor activates a G protein (tentatively called Gp) that in turn activates phospholipase
C.

This enzyme cleaves PIP2 (phosphatidylinositol-bisphosphate) into inositol

triphosphate (IP3) and diacylglycerol. Diacylglycerol activates protein kinase C, and IP3
triggers calcium release from cellular compartments. One study presented evidence that ti9THC decreased the formation of myo-inositol triphosphate in pancreatic islet cells (Chaudry
et al., 1988). This evidence implies that cannabinoids bind to a receptor that is linked to the
inositol phospholipid pathway. Yet, another study demonstrated that protein kinase C
distribution did not co-localize with cannabinoid binding (Herkenham et al., 1991a). If
cannabinoids did bind to receptors that activated this pathway, one would assume that
cannabinoid binding would co-localize with components, such as protein kinase C, of the
inositol phospholipid system. Other researchers showed that cannabinoids also stimulated
the release of arachidonic acid and phospholipid turnover (Felder et al., 1992). This effect
lacked enantioselectivity, and high concentrations were necessary.

Thus, these

investigators ruled against receptor involvement (Felder et al., 1992).
Based upon the discoveries over the past decade, one can postulate that a
"cannabinoid" neurochemical system does exist. The function of this system and its
interaction with other neurochemical systems remains unclear. It is well known that
cannabinoids exert many of their actions by influencing several traditional neurotransmitter
systems, as presented in other reviews (Dewey, 1986; Pertwee, 1988; Pertwee, 1992).
The results from numerous studies suggest that several neurotransmitters and
neuromodulators have a role in the neuropharmacology of cannabinoids. These substances

25
include acetylcholine (ACh), dopamine (DA), y-aminobutyric acid (GABA), histamine, 5hydroxytryptamine (5-HT), norepinephrine (NE), opioid peptides and prostaglandins
(PGEs). The basis for some of the effects of cannabinoids are established through the
interaction between cannabinoids and drugs that bind to other receptor types or drugs that
alter the synthesis, storage, release or metabolism of transmitters and modulators (Pertwee,
1992). Cannabinoids have been shown to enhance the formation of NE, DA and 5-HT.
Cannabinoids also stimulated the release of DA from rat corpus striatum, nucleus
accumbens and medial prefrontal cortex. GABA turnover is enhanced by cannabinoids.
The most commonly studied behavioral effects of cannabinoids include hypothermia,
antinociception and changes in locomotor activity. Results from drug interaction studies
for catalepsy and depression of spontaneous locomotor activity suggest that these effects
are mediated by ACh acting at muscarinic and nicotinic receptors, GABA acting at GABAA
and GABAB receptors and PGEs. The extrapyramidal system probably plays a role in
catalepsy since intrapallidal administration of 11-0H-b.8 -THC produced catalepsy (Pertwee
and Wickens, 1991). Evidence exists that catalepsy results from interaction of 119 -THC
with neurotransmitter systems in the basal ganglia (Gough and Olley, 1977; Gough and
Olley, 1978). Hypothermia in rats and mice has been attributed to by DA, NE, 5-HT,
GABA, histamine and opioid peptides.

There is also evidence that alteration in

thermoregulation occurs by the hypothalamus (Fitton and Pertwee, 1982) and brainstem
activity (Hosko, Schmeling and Hardman, 1981). Possibly, enhanced serotonergic
transmission (Davies and Graham, 1980) and modulated autonomic activity (Rosenkrantz,
1983) produce hypothermia. Results from hypothermia studies are often inconsistent, thus
definite conclusions cannot be drawn about the neuronal pathway involved in cannabinoid
induced antinociception (Pertwee, 1992). Several endogenous compounds serve to inhibit
nociception (NE, 5-HT, ACh, GABA, opioid peptides, PGE1 and PGD2), and some of
these compounds interact with cannabinoids to produce antinociception.
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An inwardly rectifying potassium channel co-expressed with the neuronal
cannabinoid receptor in Xenopus oocytes was activated by WIN 55,212-2 (Henry and
Chavkin, 1995). The precise role of calcium or potassium in the physiological actions of
cannabinoids remains unknown. Cannabinoids also affect serotonin (5-HT) receptors.
Anandamide, Win 55,212-2 and CP 55,940 inhibited the 5-HT3-induced current in rat
nodose ganglion neurons in a concentration dependent manner (Fan, 1995). 5-HT3
receptors may be involved in cannabinoid-induced analgesia, antiemesis and possibly other
behavioral effects.
Some experiments support the involvement of catecholamines, 5-HT, PGE1 and
opioid peptides. Interpretation of the actions of cannabinoids on neurotransmitter systems
is often difficult since evidence exists that cannabinoids both inhibit and stimulate neuronal
uptake. Relatively few studies have examined the long term-exposure of cannabinoids on
brain neurotransmitter and neuromodulator levels. As reviewed by Solowij (in press-a),
recent evidence suggests that few, if any, irreversible effects on brain chemistry exist due
to !i9-THC administration. Although it appears that neurotransmitters are altered to
produce some of the effects of cannabinoids, cause and effect have not been clearly
established.

Anandamide as an Endogenous Ligand
The discovery of a receptor raised the question about the possible existence of an
endogenous ligand and a separate cannabinoid neurochemical system. Due to the high
lipophilicity of cannabinoids, Devane et al. (1992) searched for a compound in lipid
extracts from porcine brain. They isolated anandamide, which competed for cannabinoid
receptor binding and, like !i9-THC, inhibited electrically stimulated contractions in the
murine vas deferens (Devane et al., 1992). Anandamide, a fatty acid derivative, binds both
to the cannabinoid receptor of the rat brain (Devane et al., 1992) and to murine Ltk- cells
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transfected with the human cannabinoid receptor (Childers, Sexton and Roy, 1994; Felder
et al., 1993). Anandamide produced similar pharmacological effects to t19-THC, such as

antinociception, catalepsy, hypomotility and hypothermia (Fride and Mechoulam, 1993),
and anandamide inhibited adenylyl cyclase (Felder et al., 1993) and N-type calcium
channels (Mackie, Devane and Hille, 1993). One study found that the effect of anandamide
on adenylyl cyclase was region-specific, with maximal inhibition occurring in the
cerebellum and striatum (Childers, Sexton and Roy, 1994). A comparison between
anandamide and t19-THC revealed that anandamide was 4 to 20 fold less potent and had a
shorter duration of action than t19-THC (Smith et al., 1994). Both anandamide and t19THC affected the hypothalamo-pituitary-adrenal axis in a similar manner (Weidenfeld,
Feldman and Mechoulam, 1994). Intracerebroventricular administration of anandamide
decreased CRF levels in the median eminence and increased serum ACTH and
corticosterone levels. Anandamide blocks adenylyl cyclase at the frog neuromuscular
junction, providing evidence for the presence of a cannabinoid receptor at the motor nerve
(Van der Kloot, 1994). Gap-junction conductance in striatal astrocytes is inhibited by
anandamide, suggesting that anandamide may control intercellular communication in
astrocytes and therefore neuron-glial interactions (Venance et al., 1995).
Anandamide belongs to a widespread class of natural products, the N
acylethanolamines, whose precise biological role is not fully characterized. In pig and
bovine brains, anandamide composes about 1 % of the total N-acylethanolamines (Schmid
et al., 1995). Several months after its discovery, N-arachidonic acid-2-hydroxyethylamide

(anandamide) was isolated from calf brain in an effort to find endogenous regulators of Ltype calcium channels (Johnson et al., 1993). Anandamide displaced the binding of a
calcium channel antagonist, 1,4-dihydropyridine, in cardiac and cortical membranes. This
independent finding serves to strengthen the hypothesis that anandamide is a chemical
modulator.
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One of the qualifications of a neurochemical system is the existence of a path for
synthesis and degradation of a ligand. Deutsch and Chin (1993) showed that anandamide
was rapidly taken into neuroblastoma and glioma cells. Synthesis was achieved in brain
homogenates by incubating arachidonate with ethanolamine. Anandamide was hydrolyzed
to arachidonic acid and ethanolamine by an amidase (anandamide amidohydrolase), which
resides in the membrane fractions. Degradation also occurred in brain, kidney, liver and
lung homogenates (Deutsch and Chin, 1993). The enzyme inhibitor phenylmethylsulfonyl
fluoride (PMSF) prevented degradation, but not synthesis, of anandamide.

Brain

aminohydrolase activity is selective for anandamide and is enriched in areas of the brain
with high density of cannabinoid receptors, such as the globus pallidus and hippocampus,
which suggests that this enzyme activity may be involved in the inactivation of anandamide
at its sites of action (Desarnaud, Cadas and Piomelli, 1995). Another group also found that
the distribution of anandamide hydrolytic activity correlated with the distribution of
cannabinoid-receptor binding sites; the cerebellum, cerebral cortex and hippocampus
exhibited the highest metabolic activity, while the brainstem and white matter exhibited the
lowest activity (Hillard et al., 1995). The aminohydrolase was solubilized and purified
from the microsomal fraction of porcine brain (Ueda et al., 1995). Based upon their
results, Ueda et al. (1995) suggested that the anandamide aminohydrolase and synthase
activities were attributable to a single enzyme protein.
Evidence also exists that anandamide can be metabolized by cytochromes P450s.
Mouse hepatic P450s, which are known to oxidize arachidonic acid, were found to
metabolize anandamide into 10 different metabolites (Bomheim et al., 1993). Pretreatment
of mice with P450 inducers, such as dexamethasone, phenobarbitol and 3methylcholanthrene, resulted in increased hepatic microsomal formation of several of the
anandamide metabolites (Bomheim et al., 1995). Antibodies against P450 3A prevented
the formation of several of these metabolites. Metabolism of anandamide by brain
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rnicrosomes resulted in the formation of two metabolites, only one of which was partially
inhibited by antibodies to P450 3A. The physiological consequences of P450-mediated
anandarnide metabolism remains unknown.
Two possible mechanisms for the formation of anandamide have been proposed.
Devane and Axelrod (1994) and Kruszka and Gross (1994) propose that anandarnide is
formed by the enzymatically catalyzed condensation of arachidonic acid with ethanolarnine.
Both groups demonstrated the formation of anandarnide by brain membrane preparations
incubated with arachidonic acid and ethanolamine, and both laboratories found that
arachidonic acid was the preferred substrate for the enzyme, and the reaction was specific
for ethanol amine (Devane and Axelrod, 1994; Kruszka and Gross, 1994). Kruszka and
Gross ( 1994) suggested that the condensation reaction is independent of coenzyme A and
ATP. They also propose that arachidonic acid may react with a cysteine at the active center
of the enzyme to form an arachidonyl-thiol ester enzyme intermediate. Interestingly,
Devane and Axelrod (1994) found that anandamide synthase activity was highest in the
hippocampus, followed by the thalamus, cortex and striatum, and lowest in the cerebellum,
pons and medulla. The ability of brain tissue to enzymatically synthesize anandarnide and
the presence of receptors specific for anandamide suggest the existence of anandamidecontaining neurons. Di Marzo and colleagues (1994) propose an alternative biosynthetic
mechanism. They suggest that anandarnide formation occurs through a phosphodiesterasemediated cleavage of a novel phospholipid precursor, N-a r a c h i d o n o y l
phosphatidylethanolamine (Di Marzo et al., 1994). In primary cultures of rat neurons,
stimulation with the calcium ionophore ionomycin, which increases synaptic activity, led to
the formation of anandarnide. The newly synthesized anandamide is released into the
external medium, where it can be inactivated by a rapid, saturable uptake mechanism. The
findings of Di Marzo et al. (1994) suggest that anandamide biosynthesis is under
physiological control. The condensation of arachidonic acid and ethanolamide has been
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demonstrated to occur at conditions that are non-physiological, thus giving support to the
pathway proposed by Di Marzo et al. (1994).
The establishment of a cannabinoid receptor and an endogenous ligand with
biosynthetic and degradative pathways suggests the possible presence of a distinct
neurochemical system. Anandamide may represent one member of a family of endogenous
compounds (Figure 4). Two other compounds, homo-y-linolenylethanolamide (20:3, n-6)
and docosatetraenylethanolamide (22:4, n-6), isolated from bovine brain, also competed for
cannabinoid receptor binding (Barg et al., 1995; Hanus et al., 1993) and inhibited the
electrically evoked twitch response of the mouse isolated vas deferens (Pertwee et al.,
1994). Both compounds inhibited adenylyl cyclase, and this inhibition was blocked by
pertussis toxin, indicating involvement of pertussis toxin-sensitive GTP-binding proteins
(Barg et al., 1995). The two new anandamides exerted similar behavioral effects to those
observed with fi9 -THC, including inhibition of motor activity, hypothermia, catalepsy and
antinociception (Barg et al., 1995). The maximal effect obtained with the two anandamides
in the behavioral tests were smaller than the maximal effects of fi9 -THC. Under certain
conditions, the anandamides may function as partial agonists. In a separate study, vasa
deferentia showed tolerance to the inhibitory effects of anandamide (20:3, n-6) and
anandamide (22:4, n-6) when obtained from mice pretreated with fi9-THC (Pertwee et al.,
1994). Recently, another endogenous compound, 2-arachidonyl glycerol, was isolated
from canine intestines (Figure 4) (Mechoulam et al., 1995). This compound bound to CB 1
and CB2, though with greater affinity to CB 1, and produced the typical cannabimimetic
effects in mice. 2-Arachidonyl glycerol inhibited electrically evoked contractions of mouse
isolated vasa deferentia, but was less potent and efficacious than fi9 -THC. In addition,
another group has reported that 2-arachidonyl glycerol bound to rat brain synaptosomal
membranes, and its levels in the rat brain were about a thousand times higher than that of
anandamide (Sugiura et al., 1995). Mead ethanolamide has also been proposed as a novel
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eicosanoid agonist for central and peripheral cannabinoid receptors (Priller et al., 1995).
Mead acid accumulates during periods of dietary fatty acid deprivation in rats. Priller et al.
( 1995) found that the chemically synthesized ethanolamide of mead acid bound to both CB 1
and CB2 receptor subtypes, inhibited cAMP accumulation and N-type calcium currents in
cells expressing the CB I receptor. Since anandamide is structurally related to the
leukotrienes and prostaglandins, Hampson et al. (1995) assessed anandamide as a substrate
for rat brain lipoxygenase. Lipoxygenase enzymes are important for the biosynthesis of
eicosanoids, including a number of potent oxygenated metabolites such as leukotrienes,
lipoxins and hepoxilins. Metabolites of this enzyme have been demonstrated to modulate
neurotransmission. Anandamide did serve as a substrate for rat brain lipoxygenase. One
of its metabolites, 12-hydroxyanandamide, had an affinity twice that of anandamide for the
central cannabinoid receptor (Hampson et al., 1995). 12-Hydroxyanandamide inhibited
both forskolin-stimulated cAMP synthesis and the murine vas deferens twitch response,
though it was less potent than anandamide. From these studies, a complicated picture is
emerging of anandamide interacting with several different systems. Future research must
answer numerous questions in order to advance our understanding of the physiology and
neurochemistry of anandamide in the brain. Why does such a system exist? What is its
physiological role? What would be the physical manifestations of an imbalance in this
system?

A Novel Cannabinoid Receptor Antagonist
The recent discovery of a cannabinoid antagonist provides researchers with a
valuable probe for elucidating the physiological and pathophysiological roles of the
proposed cannabinoid system. The antagonist, SR 141716A, has high affinity for the CB 1
receptor, but not the CB2 receptor (Figure 5) (Rinaldi-Carmona et al., 1994). In vitro, it
antagonized both cannabinoid-induced inhibition of adenylyl cyclase activity in rat brain
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membranes and mouse vas deferens contractions; in vivo it antagonized behavioral effects
of cannabinoid agonists (Rinaldi-Carmona et al., 1994). SR 141716A also antagonized the
discriminative stimulus effects of both t,9-THC in rats and rhesus monkeys (Wiley et al.,
1995b) and CP 55,940 in rats (Wiley et al., 1995a). This compound is the first reliable
antagonist of cannabinoid discrimination and might be useful in blocking or reversing
cannabis intoxication in humans.

SR l4 l 716A blocks activation of krox-24 gene

expression in CHO cells transfected with the human CB I receptor (Bouaboula et al.,
1995a) and prevents cannabinoid-mediated blockade of long-term potentiation in the rat
hippocampal slice (Collins, Pertwee and Davies, 1995).

Animal Tolerance and Dependence
Tolerance develops to the pharmacological effects of cannabinoids in a variety of
animal species, including pigeons, rodents, dogs, monkeys and rabbits. Several review
articles discuss the issues of tolerance and dependence (Compton, Dewey and Martin,
1990; Kaymakcalan, 1973; McMillan, Dewey and Harris, 1971; Wikler, 1976). Tolerance
has occurred to antinociception (Martin, 1985), anticonvulsant activity (Colasanti,
Lindamood and Craig, 1982), catalepsy (Pertwee, 1974), depression of locomotor activity
(Karler, Calder and Turkanis, 1984), hypothermia (Thompson et al., 1974), hypotension
(Birmingham, 1973), corticosteroid release (Miczek and Dihit, 1980), ataxia in dogs
(Martin et al., 1976) and schedule-controlled behavior (McMillan et al., 1970). Tolerance
does not develop to all cannabinoid effects, such as ACTH secretion (Dewey, Peng and
Harris, 1970). Often the levels of tolerance are markedly high with reported instances of
100-fold development. Other psychoactive cannabinoids, such as t, 8 -THC, the I!
hydroxy metabolites, nantradol and nabilone also produce tolerance (Kosersky, McMillan
and Harris, 1974; Watanabe, Yamamoto and Yoshimura, 1983). Interestingly, tolerance
also has been demonstrated in cultured cells. Tolerance developed to cannabinoid-induced
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stimulation of prostaglandin E2 production and arachidonate release (Burstein, Hunter and
Renzulli, 1985) and to cannabinoid-inhibition of adenylyl cyclase activity (Dill and
Howlett, 1988).
The precise mechanism for the development of tolerance remains unknown.
Tolerance to drugs usually occurs by two main methods: changes in pharmacokinetics or
pharmacodynarnics. Several lines of evidence indicate that pharmacokinetics (absorption,
distribution, metabolism and excretion) probably plays a minor role in tolerance production
(Dewey et al., 1973; Martin et al., 1976; Siemens and Kalant, 1974).

Thus, a

pharmacodynamic event, such as receptor down-regulation, receptor conformational
change and receptor internalization, more than likely attributes to tolerance development.
These three events result in decreased receptor-ligand interaction. Changes at the
cannabinoid receptor level following exposure to cannabinoids for a long period of time
could result in conformational changes in the receptor which would produce an altered
receptor structure, to which the ligand could not bind. Another possible pharmacodynarnic
event is receptor internalization. When receptor internalization occurs, receptors on the cell
membrane are removed into the cytoplasm where they are either degraded or recycled. The
number of receptors at the cell surface is decreased; therefore, binding to the receptor is
decreased. Several groups have demonstrated cannabinoid receptor down-regulation in
cannabinoid-tolerant animals (Oviedo, Glowa and Herkenham, 1993; Rodriguez de
Fonseca et al., 1994). Receptor down-regulation occurs when the number of receptors
made by the cells is reduced. Oviedo et al. (1993) presented data suggesting that
cannabinoid tolerance was due in part to agonist-induced receptor down-regulation.
Altered binding in animals treated acutely with �9 -THC or CP 55,940 resulted from
changes in affinity; in chronically treated animals, changes in binding were attributed to a
lowering of binding capacity. Rodriguez de Fonseca et al. (1994) found that behavioral
tolerance developed in rats chronically treated with �9 -THC.

This tolerance was
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accompanied with decreases in binding in the striatum and limbic forebrain. In a recent
study, cannabinoid binding actually increased in brain areas, such as the cerebellum and
hippocampus, after acute or chronic exposure to either anandamide or �9-THC (Romero et
al., 1995).

No changes were detected in the limbic forebrain or the medial basal

hypothalamus, and after chronic exposure receptors were downregulated in the striatum.
Interestingly, another study noted that cannabinoid receptor properties were not irreversibly
altered by chronic exposure in either rat brain 60 days following 90 days of administration
of �9-THC or in monkey brain seven months after one year of exposure to cannabis smoke
(Westlake et al., 1991 ). Receptor down-regulation could either result from or cause
alterations in gene transcription. Another study found that although a twenty-seven-fold
behavioral tolerance to �9-THC was observed, neither receptor binding nor mRNA levels
in whole brain changed (Abood et al., 1993). Fan et al. (1996) have demonstrated that an
increase in cannabinoid receptor mRNA accompanies the down-regulation of the receptor in
the cerebellum of tolerant mice. However, cause and effect has not been established (Fan
et al., 1996).
In light of the fact that most drugs which are used for recreational purposes produce
some form of physiological dependence and that development of tolerance frequently
occurs in conjunction with dependence, it would seem likely that physical dependence
would also develop following chronic exposure to cannabinoids. One of the most common
methods for demonstrating dependence, particularly for drugs which do not have a long
duration of action, is to abruptly terminate chronic administration of the agent and observe
the ensuing behavioral sequelae. Efforts to conduct abrupt withdrawal studies with
cannabinoids have produced conflicting results. McMillan et al. (1971) failed to detect
withdrawal symptoms upon termination of chronic administration of cannabinoids. A few
reports have noted that abrupt cessation of cannabinoids produce certain behavioral
changes. These alterations include increased grooming, motor activity (Kaymakcalan,
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Ayhan and Tulunay, 1977), aggression (Beardsley, Balster and Harris, 1986) and
susceptibility to electroshock-induced convulsions (Karler et al., 1984). Yet, re
administration of a cannabinoid did not reverse these effects, and other laboratories could
not duplicate withdrawal. Therefore, the capacity of cannabinoids to produce abrupt
withdrawal remains ambiguous. A second approach for assessing dependence is to
precipitate an abstinence syndrome in chronically treated animals by administering an
antagonist. The lack of a cannabinoid antagonist prompted earlier investigators to attempt
precipitated withdrawal with opioid antagonists. Naloxone was reported to precipitate
withdrawal in rats treated chronically with �9-THC, although the symptomatology differed
somewhat from that described for opioid dependence (Hirschhorn and Rosecrans, 1974;
Kaymakcalan, Ayhan and Tulunay, 1977). Fortunately, a selective and highly potent
cannabinoid antagonist was developed recently (Rinaldi-Carmona et al., 1994). This
antagonist, SR 141716A, has proven to be effective in precipitating cannabinoid
withdrawal. In one study rats were chronically infused with �9-THC for four days and
then administered the antagonist (Aceto et al., 1995). A marked change in the �9-THCinfused animals was evident approximately 10 minutes after the intraperitoneal injection of
SR 141716A, and these effects subsided within an hour. The behavioral signs included
head shakes, facial tremors, tongue rolling, biting, wet-dog shakes, eyelid ptosis, facial
rubbing, paw treading, retropulsion, immobility, ear twitch, chewing, licking, stretching
and arched back. The signs of facial rubbing and wet-dog shakes were quantified and
found to be statistically greater than that observed in vehicle-infused rats. Similar results
were observed by Tsou et al. (1995) who repeatedly injected rats with �9-THC prior to an
intraperitoneal challenge with SR 141716A. They observed that the most striking aspect of
the withdrawal syndrome was the rapidly alternating sequences of aborted fragments of
organized behavior (Tsou, Patrick and Walker, 1995). The syndrome may have resulted
from alterations in the physiology of neural circuits in the basal ganglia. These studies
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provide convincing evidence that cannabinoids can produce physical dependence. The
challenge is to understand the relationship between these animal models and the use pattern
of cannabinoids in humans. A high priority for future research is to identify the neuronal
systems which subserve the cannabis withdrawal syndrome. Manipulation of these
systems may provide a means for treating individuals who seek assistance in terminating
their cannabis use.

Pharmacokinetics and Detection
Cannabis is usually smoked as a 0.5-1 g cigarette. The THC dose necessary to
produce pharmacological effects in humans ranges from 2 to 22 mg for smoking (Martin,
1986). If only 10-25% of available THC enters the circulation when smoked, then the
dose range is actually 0.2-4.4 mg. Animal studies have shown that the THC level in the
brain is very small, with 1% of the administered dose available at peak concentration
(Agurell et al., 1986). If humans have a similar distribution, then only 2-44 µg THC
would penetrate the brain. Following inhalation, Ll9-THC is rapidly absorbed into the
bloodstream and redistributed. Initial metabolism takes place in the lungs and liver to 11hydroxy-THC (11-0H-THC). This metabolite is somewhat more potent than Ll9-THC and
more readily crosses the blood-brain barrier. More extensive metabolism in the liver
converts 11-0H-THC to many inactive metabolites, including 11-nor-carboxy-Ll9-THC
(THCCOOH), the most abundant metabolite in plasma and urine. A study by Huestis et al.
(1992) provides the first complete pharmacokinetic profile of THC and the appearance of
metabolites during cannabis smoking. THC levels increase rapidly, peak prior to the end
of smoking and quickly dissipate. Peak 11-0H-THC levels are lower than THC levels and
occur immediately at the end of smoking. THCCOOH is detected minutes after smoking,
and levels plateau for an extended period (Huestis, Benningfield and Cone, 1992). Ll9THC can be detected in blood at 7 and 18 ng/rnl after a single inhalation of smoke from a
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1.75 and a 3.55% THC marijuana cigarette, respectively (Huestis et al., 1992). An entire
cigarette will produce peak THC levels greater than 100 ng/ml (Cocchetto et al., 1981;
Huestis et al., 1992; Lemberger et al., 1972; Ohlsson et al., 1980; Perez-Reyes, Owens
and Di Guiseppi, 1981). Cannabis is also often consumed orally. Similar pharmacological
effects to smoking result, but differences exist in the rate of onset and in the blood levels of
cannabinoids. After oral ingestion, the levels of t19-THC gradually increase over a period
of 4 to 6 hours causing a delay in psychoactive effects (Wall et al., 1983). 11-0H-THC is
present in higher concentrations in blood after the oral route (Cone and Huestis, 1993).
Subsequent release of t19-THC from lipid-rich tissues occurs slowly and produces a
long elimination half-time. Estimates of elimination range from 18.7 hours to 4.1 days; the
variability in half-life measures is due to the dependence of this measure upon assay
sensitivity and timing of blood measurements (Cone and Huestis, 1993). Less variability
is found in measurements of clearance. Recent data using sensitive detection techniques
suggest that the elimination half-life in chronic users is actually three to five days
(Johansson et al., 1988). Conflicting reports exist for the clearance time of THC in light
and chronic cannabis users. Lemberger et al. (1978) reported that the time to clear half of
the dose from the body in a daily user (19 to 27 hours) is twice as fast than in an
inexperienced user. Another study did not find significant differences in clearance rates
between heavy and light users (Ohlsson et al., 1982).
Since cannabinoids affect motor skills, having a reliable measurement of
impairment similar to the breath test for alcohol intoxication is desirable. However,
establishing a relationship between blood levels of THC or its metabolites and the degree of
impairment has been difficult. This difficulty relates to the delay between peak blood
concentrations and peak drug effects (Huestis et al., 1992). Immediately after smoking,
plasma levels are high while effects are low; whereas at later times, the situation reverses.
Therefore, blood levels of THC could be useful for predicting impairment if the mode of
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administration and time of use is known. In the absence of this critical information,
attempts to develop 'cut-off levels would have to be very conservative (i.e., the values
would have to be rather high). Recently, models have been proposed to predict the time of
cannabis exposure from plasma concentrations of THC and THCCOOH (Cone and
Huestis, 1993). This model allows prediction of the elapsed time since cannabis use based
on analysis from a single plasma sample. Additional research is needed to clarify the
relationship between blood cannabinoid levels and behavioral effects.
Legal and moral concerns in the United States have led to increased efforts to detect
cannabis use in the work place and in individuals whose performance is critical for general
public safety. Initial screening tests are performed by immunoassay for the detection of
cannabinoids in urine, and positive samples are verified by gas chromatography/mass
spectrometry analysis. These assays were developed to detect the primary cannabinoid
excreted in urine, which is THCCOOH. The development of "quick tests" for the detection
of drugs of abuse results from the growing demand for simple, rapid and inexpensive on
site drug testing. The EZ-SCREEN® immunoassay test is highly sensitive for THCCOOH
and has low cross-reactivity with other cannabinoids (Jenkins et al., 1993). One of the
most frequently asked questions is the length of time required for urinary levels to fall
below detectable limits following smoking of a single cannabis 'joint'. Typically,
THCCOOH can easily be detected two to three days following smoking of a single
cannabis cigarette. Passive inhalation has become an attractive argument for explaining the
presence of urinary cannabinoids. Yet Cone et al. ( 1990) demonstrated that Herculean
efforts were required in order for passive inhalation to produce detectable urinary levels of
THCCOOH. Measurement of urinary levels of cannabinoids should be conducted solely
for the purpose of determining whether an individual has used cannabis. Attempts at
assessing impairment would require considerable knowledge of the circumstances
surrounding the last use.

Effects on Organ Systems
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Central Nervous System
Since the brain is recognized as a principle target for cannabis, research has been
conducted to study the effects of cannabinoids upon the central nervous system that extend
beyond neurochemistry. The effects of cannabis on electroencephalographic (EEG)
readings, cerebral blood flow(CBF) and brain morphology have been studied, as reviewed
by Hall et al. (1994) and Solowij (in press-a). Long term alterations in EEG recordings
have been observed in cats, rats and monkeys exposed to cannabinoids(Hall, Solowij and
Lemon, 1994). In one chronic study, monkeys were exposed to cannabis smoke for six
months (Heath et al., 1980). Serious subcortical EEG alterations were noted, with the
amygdala, hippocampus and septa) region most profoundly affected. Quantitative EEG
studies of cannabis in humans have been performed since the 1970s, and most reported an
increase in alpha power (usually relative power or alpha abundance), decreased alpha
frequency and a decrease in beta activity following acute exposure to THC (Fink et al.,
1976). These results are consistent with a state of drowsiness. Struve and Staumanis
( 1990) provide a review of the acute and chronic effects of cannabis use on the EEG
recording and evoked potential studies in humans. Recently, Struve et al.(1994) reported
that THC produced significant elevations in absolute alpha power, relative alpha power and
interhemispheric alpha coherence over frontal and frontal-central areas in chronic users.
They referred to this phenomenon as alpha hyperfrontality. In users with very long
exposure(> 15 years) EEGs were characterized by increases in frontal-central theta activity
in addition to hyperfrontality of alpha. These findings suggest that there may be a gradient
of quantitative EEG change associated with long term cannabis exposure. Infrequent use
did not produce persistent EEG change. With daily use, the topographic EEG became
characterized with hyperfrontality of alpha. At some unknown point after cumulative
exposure there was a downward shift in maximal EEG spectral power from the mid alpha
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range to the upper theta/low alpha range. Exposure of 15-30 years resulted in increases of
absolute power, relative power and coherence of theta activity over the frontal-central
cortex. The relationship between EEG changes and performance on neuropsychological
tests is not known.
Studies also have examined the effects of cannabis in humans upon two measures
of brain activity, cerebral blood flow and cerebral metabolic rate. Drug-induced changes in
these parameters are thought to represent a change in brain function (Mathew and Wilson,
1993). One study showed that acute cannabis exposure in inexperienced users produced a
global CBF decrease, whereas in experienced users CBF increased in both hemispheres,
but primarily in the frontal and left temporal regions. The authors attributed the decrease in
CBF in inexperienced subjects to their increased anxiety following cannabis administration,
and the increase in CBF in experienced users was attributed to pharmacological effects of
cannabis (Mathew and Wilson, 1992). The increased blood flow correlated with the levels
of intoxication (Mathew et al., 1992). Acute t19-THC increased cerebral metabolic rate in
humans and animals, though in humans the effects on the metabolic rate are probably
limited to specific brain areas such as the cerebellum or prefrontal cortex (Margulies and
Hammer, 1991; Volkow and Fowler, 1993). One study compared the acute effects of
cannabis on three control subjects (who had used cannabis no more than once or twice per
year) and three chronic subjects (who had used cannabis at least twice per week for at least
ten years) (Volkow and Fowler, 1993). Control subjects had an increase in metabolic
activity in the cerebellum and prefrontal cortex, and the subjects' subjective sense of
intoxication correlated with the degree of increase in metabolism in the cerebellar cortex.
Chronic users showed less change in regional metabolism and reported fewer subjective
effects, perhaps reflecting tolerance to the effects of cannabis.

Immune System
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With efforts to use either cannabis or synthetic cannabinoids for therapeutic
purposes, one should consider the potential effects on the immune system, especially in
patients with a compromised immune system, as reviewed by Hall et al. (1994).
Determining if cannabinoids impair the immune system is complicated by several factors.
First, the majority of the studies have been conducted in vitro with animal and human cell
cultures or in vivo in animals. Extrapolating these results to humans is further complicated
by the very high doses of cannabinoids used in the studies. Second, the few in vivo
human studies have produced conflicting results. Third, very few epidemiological studies
assessing disease susceptibility in heavy chronic cannabis users have been conducted.
Cannabinoids probably exert their actions through both cannabinoid receptor and
non-receptor, or nonspecific, mechanisms, since high concentrations are often needed to
elicit an effect. A nonspecific indication of an effect on the immune system is a decrease in
weight of lymphoid organs (Munson and Fehr, 1983). Cannabinoids reduced the weight
of the thymus in monkeys, and in high doses cannabinoids affected the function of the stem
cells and reduced the size of the spleen in rodents (Munson and Fehr, 1983).
The effects of cannabinoids on human, monkey and rodent macrophages have been
studied both in vivo and in vitro. Cannabinoids can affect a macrophage's morphology,
phagocytic and spreading ability, superoxide production and tumor necrosis factor and
interleukin release. Rat alveolar macrophages were only moderately affected following 30
days exposure to cannabis smoke, with changes in morphology, superoxide production
and oxygen consumption (Davies, Sornberger and Huber, 1979). Human pulmonary
alveolar macrophages obtained from cannabis smokers displayed a suppression of
superoxide production (Sherman et al., 1991). Macrophages from monkeys exposed to
cannabis smoke for up to one year had altered morphology, including an increase in the
number of vacuoles, and protein expression (Cabral et al., 1991). THC adversely affected
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the phagocytic and spreading ability of macrophages from mouse peritoneal cultures
(Lopez-Cepero et al., 1986), and similar results occurred in human mononuclear phagocyte
cultures (Spector and Lancz, 1991). Cytokine, or interleukin, production in macrophages
was also altered by THC. Interleukin 1 (ILi) bioactivity and release were increased (Klein
and Friedman, 1990; Shivers et al., 1994), and antiviral factor production was suppressed
(Cabral and Vasquez, 1992). Since tumor necrosis factor (TNF) levels were either
increased (Shivers et al., 1994) or decreased (Fischer-Stenger, Pettit and Cabral, 1993;
Zheng, Specter and Friedman, 1992) depending upon the type of cell culture, the effect of
cannabinoids on cytokine levels is probably modulatory.
The effects of cannabinoids on the humoral immunity (production of B
lymphocytes) and cell-mediated immunity (T lymphocyte production) are inconsistent.
Conflicting in vivo studies were generated in the 1970s, with cannabinoids either
suppressing human and monkey leukocyte numbers and functions (Gupta, Grieco and
Cushman, 1974; Nahas et al., 1974) or not affecting lymphocytes (Lau et al., 1976;
Rachelefsky et al., 1976; Silverstein and Lessin, 1974). These studies were often
performed with human patients without controlling lifestyle factors. In monkey studies
conducted during the same period, blood cell mitogen responses and serum antibody (IgG
and IgM) levels were significantly reduced in monkeys chronically treated with THC for
six months (Daul and Health, 1975). In another study, rhesus monkeys treated with THC
for three weeks had elevated neutrophil levels; lymophocytes were not affected (Silverman
et al., 1982). A more recent study reported that in human outpatient cannabis abusers, the

T cell CD4/CD8 ratio increased (Yvallace et al., 1988). CD4 and CDS are cell-cell adhesion
glycoproteins on the surface of T cells that act to stabilize the binding T cell receptors and
antigen complexes on the target cell. However, Dax et al. (1989) demonstrated that in
institutionalized patients receiving small amounts of cannabis for three weeks, white blood
cell and subset lymphocyte counts and killer cell activity were unaffected. When the
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amount of THC and length of exposure time increased, IgG antibody levels decreased; IgD
antibody levels increased, and IgA and lgM levels were unaffected (Nahas and Ossweman,
1991). From these studies, one can conclude that cannabis smoking appears to produce
moderate disturbances in lymphocyte activity in humans and monkeys in vivo. However,
the clinical relevance of these findings are uncertain (Hollister, 1988).
Cannabinoids also affect the function of cultured human lymphocytes. THC
suppresses leukocyte migration (Schwartzfarb, Needle and Chavez-Chase, 1974) and
lymphoproliferation (Nahas, Morishima and Desoize, 1977). Again, these effects occurred
upon exposure to high doses. Spector and Lancz (1991) showed that 11-0H-THC
suppressed natural killer (NK) cell activity. The mechanism for some of the effects of
THC might involve adenylyl cyclase activity since THC suppressed agonist-induced cAMP
in lymphocyte cultures (Diaz, Spector and Coffey, 1993). Cytokine levels in human
lymphoid cultures either increased or decreased (Watzl, Scuderi and Watson, 1991).
Many reports provide evidence that cannabinoids affect the immune system of
rodents. In vitro studies performed with rodent lymphocytes indicate that cannabinoids
suppressed antibody production (Bacztnsky and Zimmerman, 1983; Klein and Friedman,
1990), though the molecular mechanism for these effects remains unknown.

B

lymphocytes appear to be more sensitive to cannabinoid suppression than T lymphocytes
(Klein et al., 1985). Drug-induced suppression of antibody production is the most
consistently reported observation in cannabinoid studies in the immune system. The effects
of cannabinoids upon T lymphocyte proliferation do not always lead to suppression,
suggesting that cannabinoids act as modulators (Luo et al., 1992; Pross et al., 1992).
Several studies have suggested that cannabinoids decrease host resistance to
infection. Cannabinoids caused enhanced mortality in rodents to Lysteria monocytogenes
and Herpes simplex type II virus (Morahan et al., 1979). Extrapolating these results to
humans is difficult since drug doses that had the greatest effect were in the 100 mg/kg
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range. In more recent studies, bacterial infections in mice have been examined using THC
in the range of 5 mg/kg (Klein et al., 1993; Klein, Newton and Friedman, 1994). The
effects of THC on resistance to infection depended on the dose and timing of injection. If
mice were given two THC injections (8 mg/kg), one day before and one day after infection
with Legionella pneumophilia, they displayed mortality within minutes of the second
injection (Klein et al., 1993; Klein, Newton and Friedman, 1994). Animal studies
confirmed that cannabinoids decreased antibacterial (Ashfaq, Watson and E!Sohly, 1987)
and antiviral activity (Cabral, Lockmuller and Mishkin, 1986) of the host immune system.
Recent research has investigated the expression of central and peripheral
cannabinoid receptors in immune tissues (Galiegue et al., 1995). The CB I receptor is
expressed in human immune-related tissues, including bone marrow, thymus and tonsils.
Levels of CB2 receptor expression were 10-100-fold higher in immune tissues than levels
of CB I receptor expression. The rank order of CB2 mRNA in human blood cell
populations was B-cells> NK cells>> monocytes> polymorphonuclear neutrophil cells>
T8 cells> T4 cells. An immunohistological analysis performed on tonsil sections showed
that CB2 expression was restricted to B-lymphocyte-enriched areas of the mantle of
secondary lymphoid follicles. Expression of the receptors in components of the immune
system provide further evidence for cannabinoid immunosuppressive events.
Several studies have examined the effects of endogenous ligands on the immune
system. Although anandamide bound to the CB2 receptor transfected in CHO cells, it did
not inhibit CB2 coupled adenylyl cyclase activity (Bayewitch et al., 1995). Anandamide
did inhibit T and B lymphocyte proliferation and at high doses induced apoptosis
(Schwartz, Blanco and Lotz, 1994). The authors concluded that since anandamide is made
in the brain and affects the immune system, it may participate in neuroimmune interactions
(Schwartz, Blanco and Lotz, 1994). Lee et al. (1995) demonstrated that 2-arachidonyl
glycerol, but not anandamide, exhibited biological activity on spleen cell function. These

47
findings suggest that centrally produced endogenous cannabinoids are most efficacious at
mediating effects in neural tissue, and peripherally produced compounds exhibit greater
efficacy on peripheral targets (Lee, Yang and Kaminski, 1995). Additional research is
necessary to clarify the role of endogenous anandamides in the immune system.

Cardiovascular System
Cannabinoids also affect the cardiovascular system. THC can induce tachycardia,
orthostatic hypotension and decreased platelet aggregation (Clark et al., 1974; Merritt et al.,
1980; Schaefer et al., 1979). In the rat, a transient pressor response is followed by
hypotension and bradycardia (Dewey, 1986). Changes in the electrocardiogram include
varied P and T waves and decreased ST segments (Johnson and Domino, 1971 ).
Exposure to cannabinoids may aggravate pre-existing conditions such as angina and
congestive heart failure. Hypotension and bradycardia result after prolonged exposure in
humans (Benowitz and Jones, 1975). After high doses in humans, conjunctivae redden
due to dilation of blood vessels and increased heart rate with a concomitant peripheral
vasodilation (Dewey, 1986).
Recent work by Varga et al. (1995) implicates the involvement of the CB I receptor
in the hypotensive action of anandamide. Anandamide produced a brief pressor response
and a more prolonged depressor response. Only the depressor response was inhibited
upon administration of the cannabinoid antagonist SR 141716A. In addition, either
cervical spinal cord transection or blockade of cx-adrenergic receptors attenuated the
depressor response. These results suggest that the pressor component of anandamide's
cardiovascular response results from a peripheral action not mediated by the CB I receptor
or the sympathetic nervous system (Varga et al., 1995). The depressor response is due to
inhibition of sympathetic tone mediated by CB I receptors.

Human Psychopharmacology
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Cannabinoids produce a variety of acute psychological effects in humans. THC is
rapidly absorbed after smoking, and acute peak effects appear between 30 and 60 minutes.
When cannabis is ingested, the onset of action is slower, and subjective effects last for 512 hours without a clear peak. Acute subjective effects are dose-dependent. It is still
unknown whether cannabis hinders performance and produces a subtle hangover syndrome
due to residual effects of cannabinoids during the day after smoking. The subjective acute
effects of cannabis are very diverse. One characteristic of cannabis use is a state of
intoxication or euphoria and relaxation, followed by drowsiness, sedation and sometimes
depression (Hollister, 1986). Other symptoms accompanying euphoria include alterations
of motor control, sensory functions and cognitive (decision-making) processes (Nahas,
1993). Users of cannabis also claim that the drug heightens sensitivity to external stimuli,
brightens colors and enhances music appreciation. A recent extensive review concludes
that at doses which produce a moderate level of intoxication, a wide range of learned and
unlearned behaviors, including simple motor tasks and complex psychomotor and cognitive
tasks were affected (Chait and Pierri, 1992). They concluded, after an evaluation of the
literature, that cannabis adversely affected gross and simple motor tasks (body sway and
hand tremor), psychomotor behavior (rotary pursuit, Digit Symbol Substitution, reaction
time, accuracy in divided attention and sustained attention). Cannabis had weak effects on
simple reaction time and inconsistent effects on hand-eye-coordination. Data from
Heishman et al. ( 1990) indicate that cannabis can impair complex human performance in
arithmetic and recall tests up to 24 hours after smoking.
Scientific evidence suggest that marijuana impairs memory and learning. �9-THC
causes its greatest and most consistent effects in short-term memory, as measured in free
recall of previously learned items. The major impairment by cannabis in free recall studies
produces substantial increases in memory intrusions (Chait and Pierri, 1992). Neither
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immediate and sustained attention nor controlled retrieval from semantic memory were
affected. Thus, THC probably impairs acquisition and working memory but not retrieval
processes. The effects of cannabis upon recall in the digit span, recognition and paired
associate memory performance tasks have been inconsistent (Chait and Pierri, 1992;
Schwartz, 1993). Generally, cannabis did not affect the retrieval of previously learned
facts. Although the acute effects of THC on memory appear modest, there are concerns
about the effects of chronic use upon adolescent development.
THC does alter time perception, producing an overestimation of elapsed time (Chait
and Pierri, 1992). Associated with the altered time sense is temporal disintegration, which
is defined as difficulty in retaining and coordinating memories and perceptions relevant to a
goal the user is perusing (Melges et al., 1970). The effect of changed time perception and
short-term memory disruption might be reflected in decreased driving and occupational
skills, but evaluation of work productivity in chronic users has not detected major
decrements in work performance (Hollister, 1986).
Impairment of both cognition and motor control has been documented in a
laboratory setting and proposed as a contributor to accident and traffic fatalities (Aussedat
and Niziolek-Reinhardt, 1993) and non-vehicular accidents (Soderstrom et al., 1993).
However, based upon a review of the literature, no clear relationship has been shown
between cannabis smoking and either seriously impaired driving performance or the risk of
accident involvement. The extent that cannabis contributes to traffic accidents is not known
with certainty. Results from laboratory studies and driving simulations are reviewed
extensively by Chesher ( 1995) and Rabbe (1994 ). Laboratory studies have shown
performance impairment occurring after inhaled doses of cannabis as low as 40 µg/kg.
Cannabis produces a dose-dependent impairment on specific skills, which become
pronounced after 100-200 µg/kg doses. In particular, tracking, divided attention and
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vigilance tests performance are affected by THC. In contrast, results from driving
simulator and closed-course tests surprisingly indicate that THC in single-inhaled doses up
to 250 µg/kg has relatively small effects on driving performance. Explaining the disparity
in results obtained in laboratory studies and in driving simulations is difficult. Recently,
Robbe (1994) performed a series of studies which evaluated the effects of cannabis
smoking on actual driving performance and compared these results to the effects of alcohol
on driving. Several driving tests were employed including maintenance of a constant speed
and lateral position during uninterrupted highway travel, following a lead car with varying
speed on a highway and driving in a city. Cannabis produced a moderate degree of
impairment, which was related to the THC dose. At a dose of 300 µg/kg THC impaired
road tracking ability and slightly impaired the ability to maintain a constant headway when
following another car. A low THC dose (100 µg/kg) did not impair driving ability in the
city to the same extent as a blood alcohol concentration of 0.04%. Drivers under the
influence of marijuana tended to overestimate the level of impairment and compensate by
concentrating on driving and/or slowing down. In contrast, drivers under the influence of
alcohol tended to underestimate the effects of alcohol and not make allowances for
impairment. Several studies have also attempted to determine the incidence of cannabis
involved in road crashes in which the driver had consumed cannabis and was responsible
for the collision. Three studies have reported that cannabis-bearing drivers were no more
responsible than the non-drug-bearing drivers (Drummer, 1994; Terhune et al., 1992;
Williams et al., 1985). This finding must await clarification until sample sizes are greatly
increased. Robbe (1994) concluded that while campaigns to discourage the use of cannabis
by drivers are warranted, concentrating upon cannabis alone may not be in proportion to
the safety problem it causes.
Several factors complicate the interpretation of cannabis-induced impairment, such
as co-use with other drugs, variability among individuals, development of tolerance and
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intrinsic difficulties in conducting a systemic evaluation in the general population.
Cannabis is often co-abused with other drugs, such as alcohol. Co-use of cannabis with
alcohol (Wechsler et al., 1984) or phencyclidine (PCP) (Poklis, Maginn and Barr, 1987)
might augment cannabis' effects. Results indicate that performance disruption was greater
for alcohol-induced impairment in combination with cannabis (Hollister, 1986). It has
been reported that ethanol-induced dose-dependent decrements in performance skill
required for automobile driving were further exacerbated by cannabis (Perez-Reyes et al.,
1988). Tolerance does develop during chronic exposure to high quantities of cannabis, but
the degree of tolerance following intermittent exposure to cannabis is less definitive
(Hollister, 1986). Detecting cannabis intoxication by motor performance in an experienced
user may be difficult unless a complex performance task is assessed or if the user has had
experience in the task (Chait and Pierri, 1992). Cannabis intoxication in an inexperienced
user is readily detectable by many performance tests. Establishing a degree of correlation
between the level of impairment and blood concentrations of cannabinoids would aid in
determining causality in accidents. In chronic users, tolerance may develop to some of the
acute effects. Thus, the level of intoxication is more difficult to detect in an experienced
user except in novel tasks or tests requiring a great deal of skill or manual dexterity (Chait
and Pierri, 1992). Given the confounding factors discussed above, it is unlikely that
measures of �9-THC and its metabolites will become standards for intoxication.
Human studies have been conducted to determine if a state-dependent learning
effect exists for cannabis. The first evidence of a cannabis-induced state dependency was
reported by Abel ( 1970). Subjects learned narrative material while exposed to cannabis and
were tested in a sober or cannabis-intoxicated state (Abel, 1970). A greater deficit of recall
was recorded for subjects tested in the sober state. Evidence also exists that the state
dependent learning effects of cannabis are most apparent in tasks using sequential memory
(Hill et al., 1973; Stillman et al., 1974). The state-dependent learning effect for cannabis is
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observed in memory tasks rather than psychomotor or adversely motivated tasks (Jarbe et
al., 1993). Difficult tasks, such as active recall, are also affected by state-dependent
learning (Hirbe et al., 1993). In order to determine the influence of the frequency of use
upon cannabis' effects on memory, one study differentiated between heavy and social users
(Cohen and Rickles, 1974). Subjects in the heavy-user group average smoking cannabis
five to six times per week for a year. The social-user group smoked on weekends. The
frequency of use had profound effects on the state-dependent learning effects of cannabis.
In recall tests, social-users did exhibit state-dependent effects, whereas heavy users did
not. The heavy-user group performed equally well whether intoxicated or not, and they
performed better in recall than social-users.
Since one of the well known acute effects of cannabis is to impair cognitive
functioning, it has long been suggested that chronic cannabis use may cause lasting
cognitive impairments. Assessing the chronic effects of cannabis or any other psychoactive
drug on cognitive functioning is often difficult since many factors other than drug use must
be controlled. Difficulties encountered when attributing cognitive effects to psychoactive
drugs include determining levels of cognitive impairment, which might have preceded drug
use, determining the duration and frequency of drug use and taking into account effects of
multiple drug use. It has been proposed that chronic use might result in long term memory
impairment (Schwartz, 1993). Yet, previous reviews have generally concluded that
evidence is insufficient to conclude that long term use of cannabis produces lasting gross
cognitive impairment (Wert and Raulin, 1986). Solowij (in press-b) and Pope et al. (1995)
have reviewed recent, more methodologically rigorous research which used improved test
procedures and electrophysiological methods. These findings provide evidence that
cannabis produces complex and subtle impairments, which are related to the duration of
cannabis use. Impairments appear specific to higher cognitive functions, such as the
organization and integration of complex information involving attention and memory
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processes (Solowij, in press-b). It has been hypothesized that long term cannabis use
impairs the frontal lobe, an area of the brain which functions in the temporal organization of
behavior. This hypothesis is consistent with the altered perception of time and with
cerebral blood flow studies which demonstrate greatest effects in the frontal lobe region.
Recent studies also suggest that impairment assessed by sensitive measures of brain
function can be detected after only five years of use. Not all individuals are affected
equally by long term use, and often the effects are subtle. However, one should not
underestimate the effects of even subtle impairment of cognitive functioning on daily life.
Great interest has been generated in the effects of cannabis upon adolescent
development and educational performance and production of a cannabis-induced
"amotivational syndrome." A modest statistical relationship may exist between cannabis
and other illicit drug use and poor educational performance (Schwartz, 1993). Some
individuals suffer no memory impairment at all, whereas those individuals who already
have a learning disability are more susceptible to memory disruptions than a gifted student
group (Schwartz, 1993).

Attempts to verify the existence of a cannabis-induced

"amotivational syndrome" have failed (Dewey, 1986; Foltin et al., 1989; Foltin et al.,
1990; Hollister, 1986). The lack of motivation observed in some individuals more likely
results from psychosocial problems and polydrug use rather than solely cannabis use
(Taschner, 1983). Additional research should address the impact of long term cannabis use
on cognitive development in adolescents.
Since THC produces diverse psychological effects in humans, it has been
suggested that cannabinoids might induce psychopathological states (George, 1970; Talbott
and Teague, 1969). However, identification of a specific "cannabis psychosis" even in
chronic, heavy users has not occurred (Dewey, 1986; Hollister, 1986; Thornicroft, 1990).
Cannabis does appear to worsen symptoms of some preexisting mental disorders, such as
schizophrenia (Negrete, 1993). Even though paranoid schizophrenics recognize the
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worsening of their disorder with cannabis use, many still continue to try to self-medicate
themselves with the drug. Cannabis increases hallucinations and delusions and produces
inconsistent results on the symptoms of social withdrawal and lethargy. While some
investigators believe that cannabis use does lead to the development of schizophrenia,
conclusive evidence does not exist that cannabis is a causative factor in the development of
schizophrenia (Allebeck, 1993; Negrete, 1993). Individuals abusing cannabis who also
develop psychiatric problems may suffer from rapid onset schizophrenia (Allebeck, 1993).
Since most of these individuals are poly-drug users, it seems more likely that cannabis or
any of the other abused drugs might act as a trigger for precipitating latent schizophrenia.
The relative risk of developing psychiatric problems in the general population of cannabis
users is apparently very small. Proper studies comparing the development of disorders in
abusers and non-abusers have not been performed. However, given the world-wide and
prevalent use of cannabis, one would expect to see more reported cases of cannabis
induced psychiatric disorders if cannabis readily caused them.

Human Tolerance and Dependence

In the late 60s and early 70s, there was considerable confusion regarding the
development of tolerance to smoking cannabis. The well known phenomenon that many
newcomers required several smoking episodes before experiencing the cannabis 'high' led
to the hypothesis that "reverse tolerance" developed. The notion that tolerance could then
develop to cannabis' psychotomimetic effects formed the basis of the proposed "reverse
reverse tolerance". There is no doubt that many factors, other than the inherent properties
of ,:19 -THC, are contributors including potency of the cannabis, expectations,
environmental influences, individual differences and frequency of use, to name just a few.
Yet, convincing evidence exists for the development of tolerance to 119-THC in humans
(Jones, Benowitz and Bachman, 1976), as was described above for animals. Tolerance
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developed to a variety of ,19 -THC's effects, following oral administration, including
cannabinoid-induced decreases in cardiovascular and autonomic functions, increases in
intraoccular pressure, sleep disturbances and mood changes (Jones, Benowitz and
Bachman, 1976). Results are less conclusive for behavioral tolerance. To achieve
behavioral tolerance, high doses of ,19 -THC were administered for a sustained period of
time. In one study, tolerance to the subjective effects of ,19 -THC developed after oral
administration (10 mg) for several days; greater tolerance developed with increased
amounts of the drug (Jones, 1983). Thus, if the doses of ,19 -THC are small and
infrequent, little behavioral tolerance develops. High doses must be given for long periods
of time to produce tolerance.
Although it is established that chronic cannabis use does not result in severe
withdrawal symptoms, numerous case reports attest to development of dependence (Jones,
1983). Several early reports came from countries where potent cannabis was used for long
periods of time. Upon deprivation of cannabis, users experienced auditory and visual
hallucinations and irritability (Fraser, 1949). Since that report, the development of
tolerance and dependence have been studied under rigorous and controlled conditions
(Jones, 1983; Jones and Benowitz, 1976; Jones, Benowitz and Bachman, 1976; Jones,
Benowitz and Heming, 1981). In one study, a 30 mg dose of cannabis extract or ,19 -THC
was administered orally approximately six times per day for up to 21 days. The most
prominent symptoms upon cessation of administration were increased irritability and
restlessness. Other symptoms, though variable, included insomnia, anorexia, increased
sweating and mild nausea. Objective symptoms were increased body temperature, weight
loss and hand tremor. Re-administration of a cannabis cigarette or oral ,19 -THC alleviated
the objective and subjective effects, suggesting the establishment of a withdrawal
symptom.

Potential Therapeutic Uses
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The prevalence of cannabis use has resulted in intense efforts of cannabis research
for the past several decades. Attempts have been made to discern the pharmacology of
cannabis and the mechanism of action producing the psychoactive effects. In addition to
exploring the euphoric effects of cannabis, emphasis has been placed upon the drug's
therapeutic potential. Early crude preparations of cannabis were used to treat allergies and
migraines and to facilitate childbirth (Mechoulam, 1986). The effective component, 119_
THC, was also used for alleviating pain, glaucoma, muscle spasticity, bronchial asthma
and nausea (Hollister, 1986). However, the lack of evidence that cannabinoids are better
than other drugs currently in use limits their clinical usefulness, and separating the
undesired side effects of cannabis from the therapeutic effects has proven difficult. In
addition, schedule II drugs require extensive record-keeping and cause other administrative
problems. Pharmaceutical companies have marketed only 119-THC which is used primarily
as an antiemetic for cancer chemotherapy patients. The development of a cannabinoid
analog possessing greater pharmacological selectivity is an important aim for future
cannabinoid research.
Although many useful probes for determining the underlying mechanism of action
for cannabinoids have been produced, no clinically relevant compound has emerged. The
inability to separate the various pharmacological and psychoactive properties of the
compounds remains the greatest impediment. Cannabinoids have generated interest over
the centuries for their alleged ability to treat a wide range of disorders. Possible therapeutic
uses include treatment of bronchial asthma, nausea, vomiting, pain, convulsions,
glaucoma, muscle spasticity and loss of appetite (Hollister, 1986). Cannabinoids also
represent a novel way to treat disorders not responding to traditional agents or therapies.
Current debate in this country centers upon the possible legalization of cannabis for
medicinal purposes. Proponents of legalization believe that the availability of THC for
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medicinal purposes would eliminate the need for the crude plant product. While there may
be some merit in legalization arguments, the development of a potent and selective
cannabinoid possessing greater efficacy than current drugs would, of course, end the
ongoing debate.
Cannabis has been used most frequently for treating refractory nausea and
vomiting. In 1987, the United States Food and Drug Administration approved dronabinol,
a L\9 -THC formulation in sesame oil, for treatment of chemotherapy-induced nausea and
vomiting not responding to other agents. Dronabinol has been useful, though some
patients dislike the psychotropic effects and somnolence. L\9 -THC has gained orphan
status by the FDA to treat nausea from chemotherapy and to stimulate appetite in AIDS
patients. Results from clinical trials have suggested that the drug improves appetite (Plasse

et al., 1991). However, one should remember that extensive animal studies indicate that
cannabinoids adversely affect the immune system.

Should a drug with possible

immunosuppressive properties be given to patients who already have a compromised
immune system? Only future research and more extensive clinical evaluation will determine
if L\9-THC truly benefits these individuals.
Drug development also has focused upon the potent antinociceptive properties of
cannabinoids. Great progress would be made in synthesizing an analgesic agent lacking
the side effects and abuse liability of opioids. Unfortunately, cannabinoids produce
antinociception at doses that also elicit other behavioral effects, such as sedation,
hypothermia and catalepsy. Cannabinoids have a distinct pharmacological profile from the
opioids and may act through a different mechanism for alleviating pain. Recent research
demonstrated that a kappa receptor antagonist, nor-binaltorphimine (nor-BNI), blocked
cannabinoid-induced antinociception, but did not affect the other behaviors (Smith, Welch
and Martin, 1993). Perhaps this compound could be used to understand the mechanism of
action for cannabinoid analgesia.

Dissertation Objectives
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After years of research, anandamide has been proposed to be the elusive
endogenous ligand for the cannabinoid receptor. Anandamide possesses many of the same
pharmacological effects as �9 -THC and other exogenous cannabinoids, including
production of antinociception, inhibition of locomotor activity, catalepsy and decrease in
body temperature in mice. In vitro, anandamide mimics cannabinoids by inhibiting both
forskolin-stimulated increases in adenylyl cyclase activity and the electrically-evoked
murine vas deferens twitch response. Although anandamide does generate many of the
same effects as other cannabinoids, differences do exist. The discovery of anandamide and
other similar endogenous compounds provides the opportunity to investigate and
understand the purpose of this novel neurochemical system. One of the problems
encountered at the onset of anandamide research was the susceptibility of this compound to
metabolism in both in vitro and in vivo systems.

Developing a potent and stable

anandamide analog would greatly facilitate determining the physiological and
pharmacological role of anandamide. Examination of the structures of anandamide, CP
55,940, the potent bicyclic cannabinoid, and SR 141716A, the proposed antagonist of the
central cannabinoid receptor, reveals great structural diversity. Anandamide is a fatty acid
derivative. CP 55,940 is produced by the opening of the B ring in three ring system. �9THC and SR 141716A vastly differ in structure from either compound. The structural
differences raise the question as to whether these three compounds are binding to the same
receptor in the same manner.
While the discovery of anandamide provides an answer to the type of endogenous
compound that binds to the cannabinoid receptor, many questions remain. The purpose of
this dissertation is to investigate anandamide's interaction with the central cannabinoid
receptor. The specific aims of this research are to:
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I) Determine which structural features of anandamide are important for interaction
with the central cannabinoid receptor, as assessed by in vitro binding studies and in vivo
behavioral experiments
2) Structurally modify the template of anandamide in order to develop more potent
and metabolically stable compounds
3) Characterize anandamide's binding to the cannabinoid receptor in the CNS by
comparing anandamide's receptor binding affinities, as determined from autoradiographic
experiments in rat brain from selected brain areas
4) Compare anandamide's receptor binding densities to the binding densities and
patterns of two other compounds, CP 55,940 and SR 141716A, that bind to the central
cannabinoid receptor
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II. Evaluation of Cannabinoid Receptor Binding and
in Vivo Activities for Anandamide Analogs

Introduction
Marijuana, or Cannabis sativa, is one of the oldest and most widespread drugs of
abuse in use today. The psychoactive constituent of cannabis, ,19-THC, produces a unique
pattern of behavioral effects, which include antinociception, catalepsy, anticonvulsive
activity, hypothermia, hyperexcitability and depression of motor activity in a wide variety
of animal species (Dewey, 1986). Structure-activity relationship studies suggested the
existence of a specific cannabinoid receptor through which ,19-THC exerted behavioral and
central effects (Razdan, 1986). The development of potent synthetic bicyclic cannabinoid
agonists, such as CP 55,950, allowed for the characterization of a specific saturable high
affinity cannabinoid binding site in rat membranes (Devane et al., 1988). The structureactivity profile indicated a correlation between cannabinoid receptor binding and
pharmacological and behavioral effects (Compton et al., 1993).
Our understanding of the cannabinoid system has progressed in a somewhat nontraditional manner in that characterization of the second messenger system proceeded the
receptor binding studies. The expression of the cannabinoid receptor within the brain
suggested the existence of an endogenous ligand. In 1992 a candidate ligand isolated from
porcine brain displaced [3H]-HU 243, a cannabinoid receptor ligand, from synaptosomal
membranes in a dose-dependent manner (Devane et al., 1992). The purified compound
was determined to be arachidonylethanolamide, or anandamide, a derivative of arachidonic
acid which bears no obvious structural similarity to either ,19-THC or CP 55,940. Like
other cannabinoids, anandamide inhibited forskolin-stimulated cAMP production in CHO
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cells expressing the human cannabinoid receptor and inhibited N-type calcium currents
through a pertussis toxin-sensitive G protein (Felder et al., 1993; Mackie et al., 1993;
Vogel et al., 1993).

Anandamide produced effects similar to ti9 -THC, including

antinociception, hypomotility, hypothermia and catalepsy in mice (Fride and Mechoulam,
1993; Smith et al., 1994). However, anandamide differed pharmacologically from !i9THC in that anandamide had a shorter duration of action in behavioral assays, was less
potent and possessed different antinociceptive properties (Smith et al., 1994).
It is highly likely that metabolism plays a role in the short duration of action of
anandamide. The issue of metabolism was first raised with the report that PMSF
(phenylmethylsulfonyl fluorine), an enzyme inhibitor of serine proteases, some thiol
proteases and esterases such as erythrocyte acetylcholinesterase, interfered with the
degradation of anandamide by inhibiting an amidase (Deutsch and Chin, 1993). Initial
binding studies with anandamide competition for [3H]-WIN 55,212-2 resulted in
anandamide exhibiting low affinity for the receptor (Childers et al., 1994). These
researchers discovered that the addition of PMSF to the incubation condition allowed
anandamide interaction with the receptor. Subsequent binding studies performed in our
laboratory supported this finding in that the binding affinity of anandamide was enhanced
several hundred fold with the addition of PMSF (Smith et al., 1994). The fact that
anandamide was found in brain and that both synthetic and degradative enzymes for
anandamide are present in brain provide strong support for anandamide being an
endogenous cannabinoid.
Anandamide had a shorter duration of action and more rapid onset than ti9 -THC
(Smith et al., 1994). The shorter duration of action could be due to metabolic differences
rather than separate mechanisms. Anandamide is metabolized to arachidonic acid by an
amidase (Deutsch and Chin, 1993), whereas ti9 -THC is not. Although anandamide
produced antinociception, the mechanism by which it does so may be different than Li9 -
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THC since nor-BNI, a kappa opioid antagonist that blocks t:;.9 - T HC-in d u c e d
antinociception, did not block anandamide-induced antinociception (Smith et al., 1994).
While much evidence supports anandamide being the endogenous ligand, this dissimilarity
demonstrates that the actions of anandamide and t:;.9-THC are not identical.
At the present time, only limited structure-activity evaluations have been conducted
with anandamide (Felder et al., 1993; Mechoulam et al., 1994). The first objective of this
study was to determine the structural requirements important for anandamide's interaction
with the cannabinoid receptor. To accomplish this objective, rapid filtration binding studies
employing [3H]-CP 55,940 as the radioligand were conducted in the presence and absence
of PMSF. Behavioral activity was assessed by the ability of the analogs to produce
hypomotility and antinociception. The affinities of anandamide analogs for the binding site
were correlated with in vivo pharmacological potencies. These correlations were then
compared to those obtained for other cannabinoid agonists. The second objective was to
develop metabolically stable and potent analogs of anandamide. If compounds were stable
in binding experiments both with and without addition of an enzyme inhibitor, then these
compounds might also be stable in vivo. Analogs with increased potency and stability
would aid in the determination of the physiological role of anandamide.

Materials and Methods
Male Sprague-Dawley rats (150-200 g) and male ICR mice (18-25 g), both from
Harlan (Dublin, VA), received food and water ad libitum and were maintained on a 14: 10
hr light/dark cycle. CP 55,940 was a gift from Dr. L. Melvin of Pfizer Inc., Central
Research Division (Groton, CT). [3H]-CP 55,940 and [3H]-anandamide were purchased
from DuPont-NEN (Wilmington, DE). [3H]-Anandamide was labeled at carbons 5, 6, 8,
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9, 11, 12, 14 and 15. All anandamide analogs were prepared by Dr. Raj Razdan of
Organix Inc. (Woburn, MA).
Dru2 preparation and administration. For binding assays, compounds were
prepared as l mg/ml stock solutions in absolute ethanol and were stored at -20 °C. If
employed in behavioral assays, drugs were dissolved in a 1: 1: 18 mixture of ethanol,
emulphor (International Specialty Products, Linden, NJ) and saline (0.9% NaCl) and were
administered intravenously (i.v.) in the mouse tail vein in volumes of 0.1 ml/10 g of body
weight.
Bindin2 assays. Radioligand binding to P2 membrane preparations was
performed as described elsewhere (Compton et al., 1993), with the exception that P2
pellets were prepared from whole rat brains, not cortices. Ethanolic 1 mg/ml stock
solutions of anandamide, anandamide analogs and CP 55,940 were diluted in buffer (50
mM Tris-HCI, 1 mM EDTA, 3 mM MgC12 and 5 mg/ml BSA) without evaporation of the
ethanol (final concentration not exceeding 0.4%). Saturation studies were performed to
determine the Kd of CP 55,940 in the presence and absence of PMSF (50 µM). [3H]-CP
55,940 (50 pM - 10 nM), competing unlabeled CP 55,940 ( l µM) and sufficient buffer to
bring the final reaction volume to 1 ml were added to siliconized glass tubes. Binding was
initiated with the addition of 150 µg of membrane protein. In competition studies, analog
concentrations ranging from 1 nM to 10 µM and a 1 nM concentration of [3H]-CP 55,940
were used. Nonspecific binding was determined in the presence of 1 µM CP 55,940.
Saturation and competition experiments were also performed with and without 50 µM
PMSF. After a one-hour incubation at 30 °C, the reaction was terminated with the addition
of 2 ml ice-cold buffer (50 mM Tris-HCI, 1 mg/ml BSA) followed by rapid filtration
through PEI-treated filters. The assays were performed in triplicate, and the results
represent the data from three to six independent experiments.
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Behavioral evaluations. Mice were acclimated to the laboratory overnight.
Depression of locomotor activity was measured by placing mice into individual photocell
activity cages (11 x 6.5 in) 5 min following an i.v. injection. For the next 10 min the total
number of beam interruptions in the 16 photocell beams per cage were recorded using a
Digiscan Animal Activity Monitor (Omnitech Electronics Inc., Columbus, OH).
Spontaneous activity (SA) was expressed as percent of control activity. Antinociception
was assessed by measuring the tail-flick (TF) response to a heat stimulus (Dewey et al.,
1970). Control latencies of 2 to 4 sec were obtained for each animal with a standard tailflick apparatus prior to drug or vehicle administration. A 10 sec maximum latency was set
to avoid tissue damage. Mice then were re-tested 15 min after drug injection, and
differences in latencies to the tail-flick response were recorded. Each dose tested in the
antinociception and hypomotility assays represents a separate group of animals (six mice
per group). Antinociception was expressed as the %MPE (maximum possible effect),
which was calculated as:
!(test latency - control latency)
%MPE =
]
[ (10 sec - test latency)

X

100.

Time Course Study. Animals were injected i.v. with either anandamide,
compound 16 or vehicle. At 5, 15, 30 and 60 min following injection, the animals were
tested in the tail-flick assay. Separate groups of animals (six mice per group) were used for
each time point and drug.
Anandamide Metabolism in the Receptor Binding Assay. [3 H ]
Anandamide (0.1 µCi) (specific activity = 207 Ci/mmol), 1.5 µM anandamide, 150 µg
membrane protein and sufficient buffer to bring the final reaction volume to 1 ml were
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added to siliconized glass tubes. The experiment was performed either with or without
PMSF (50 µM) in triplicate. Following a one-hour incubation at 30 °C, samples were
extracted twice with 2 ml acidified ethyl acetate. The organic layer was filtered through
glasswool, dried completely and re-suspended in 500 µl ethanol. Samples were analyzed
by high performance liquid chromatography.

The mobile phase was composed of

MeOH:H20:acetic acid (85: 15:0.05). A reverse phase C l 5 5 µm absorbance column was
used with a 50 mm hand-packed guard column in line. Sample flow rate was 1 ml/min for
30 min through a radiomatic detector with a scintillant flow of 3 ml/min.
Data Analysis. The Bmax and Kct values obtained from the Scatchard analysis
(Rosenthal, 1967; Scatchard, 1951) of the saturation experiments were calculated from the
KELL binding analysis programs for the Macintosh computer (Biosoft, Milltown, NJ).
ICso values for the analogs were determined and then converted to Ki values (Cheng and
Prusoff, 1973). Statistical evaluation of parallelism between displacement curves generated
in the presence and absence of PMSF were performed using ALLFIT (De Lean, Munson
and Rodbard, 1978). Dose-response relationships were determined for each analog in the
pharmacological assays. Antinociception and hypomotility data were converted to probit
values, and ED50's were calculated by unweighted least-squares linear regression analysis
of the log dose versus the probit values. Statistical analysis of the behavioral data was
performed using ANOV A with Dunnett's t-test for comparison to the vehicle group.
Comparisons between binding data (log Ki) and behavioral data (log EDso values
expressed in µmol/kg) were made with the Spearman rank order correlation test.

Results
Scatchard analysis. Saturation experiments were conducted in the absence and
presence of 50 µM PMSF to determine if PMSF altered the affinity of [3H]-CP 55,940 for
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the binding site in whole brain P2 membranes. Computer analysis of saturation data
(means

± S.E., n = 5) without PMSF indicated a Kd of 580 ± 70 pM, a Bmax of 2.09 ±

0.23 pmol/mg protein and a Hill coefficient of 0.96
produced a Kd of 1030
coefficient of 0.94

± 0.05. Incubation with PMSF

± 130 pM, a Bmax of 2.25 ± 0.19 pmol/mg protein and a Hill

± 0.02 (means ± S.E., n = 5). Bmax and Hill coefficient values were

the same in the presence and absence of PMSF. However, the addition of PMSF produced
a statistical difference, as determined by Dunnett's t-test (P < 0.05), between the Kd values.
The Ki's of the analogs were calculated using the appropriate Kci of [3H]-CP 55,940.

Determination of Analog Affinity Constants. One of the main objectives of
this investigation was the identification of structurally important features of anandamide
required for cannabinoid receptor binding. Anandamide, an eicosanoid with cis double
bonds at carbons five, eight, eleven and fourteen, is composed of arachidonyl and
ethanolamide moieties joined through an amide linkage. The ability of anandamide to
compete for [3H]-CP 55,940 binding is depicted in Figure 6. The average Ki with PMSF
was 89 ± 10 nM (n = 4). The average Ki increased to 5400 ± 1600 nM (n = 3), and the
displacement curve shifted to the right when PMSF was not added. Since the affinity of
anandamide was substantially decreased without the addition of an enzyme inhibitor, all
displacement experiments were routinely performed in the presence of PMSF. Selected
analogs were subsequently evaluated in the absence of PMSF to assess the influence of
metabolism on binding. If an analog exhibited low affinity in the presence of the amidase
inhibitor, additional binding studies were not repeated without PMSF.
Chemical modifications made to the backbone of anandamide created a diverse
series of anandamide analogs. The first series of compunds consisted of changes in the
double bond arrangement (Table 1). When a single double bond was placed at carbon 11,
as in compound 1, a Ki of greater than 10,000 nM was obtained, as compared to
anandamide's Ki of 89 nM. Any compound displaying a Ki of 10,000 nM or greater was

67

100

=
e
·-

.....

75

�
�
C.J

elS
Q.
r.r:i

50

�

�

25
0

-9

-8

-7

-6

-5

-4

Log Anandamide [M]

-3

Figure 6. Anandamide displacement of [3H]-CP 55,940 binding in the absence and
presence of 50 µM PMSF. The data are presented as percent displacement of total binding.
The Ki in the presence ( •) of PMSF was 89 ± 10 nM; in the absence ( +) of PMSF the Ki
equaled 5400 ± 1600 nM. Ki= mean± S.E. of at least three experiments each performed
in triplicate.
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considered inactive in the binding assay. Adding a fifth double bond at carbon 17 resulted
in an analog (compound 2) with a Ki of 1470 nM. Thus, these double bond changes in the
anandamide backbone produced compounds with lower binding affinities to the receptor.
Ki's were not determined without PMSF for compounds 1 and 2. Compounds 3 and 4
were completely saturated, and in compound 4 a 2'-fluoroethyl group replaced the 2'
hydroxylethyl group. However, these compounds were insoluble in ethanol which
prevented the determination of their K i 's.
Analogs also were synthesized with changes in the ethanolamide constituent, as
listed in Table 2. Replacement of the N-ethanolamide with either a hydroxypropyl or a
hydroxypentyl group, as in compounds 5 and 6, respectively, resulted in analogs with
lower affinity than that of anandamide. Therefore, progressively lengthening the N
substituent chain decreased the affinity of the analogs. In compound 7 substitution of the
ethanolamide constituent with a sulfonamide functional group resulted in a compound with
a Ki close to that of anandamide. The Ki increased significantly without PMSF, although to
a somewhat lesser extent than with anandamide.

Substitution with a

bromobenzenesulfonamide (compound 8) created an inactive analog. The morpholine
derivative of anandamide (compound 9) had an affinity that was approximately 10 times
less than anandamide in the presence of PMSF.
A third series of analogs was synthesized in which several subsitutents were
substituted for the hydroxyl in anandamide (Table 3). Substitution with bulky sulfonamide
(compound 10) or phenoxyethyl (compound 11) groups produced analogs with affinities
less than anandamide in the presence of PMSF, with the sulfonamide derivative having
higher affinity than the phenoxyethyl derivative. Both compounds in the absence of PMSF
had Ki's approximately two times higher than in the presence of PMSF. However, their
affinities in the absence of PMSF were less than that of anandamide in the presence of
PMSF. Substitution of the hydroxyl group with a fluorine moiety (compound 12), yielded
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Table 1. Comparison of pharmacological potency and receptor affinities of anandamide
analogs with varying degress of saturation.

K (PMSF)
(nM)

Structure

Compound

(nM)

S.A.
FD so
( mol/k )

Tail-Flick
( mol/k )

H I'
��OH

II 12

20

2'

Anandamide

89± 10

5400 ±1600

50.3

17.4

> 10,000

nd"

77.2

110.3

1470 ± 500

nd

167.1

141.9

50.3

261.5

5.3

10

��OH

2

�� OH

d;� OH

0
�F

4

'not detennined
tunable to detennine due to solubility problems
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Table 2 Comparison of pharmacological potency and receptor affinities of anandamide
analogs with substitutions for ethanolamide.

Structure

Compound

K; (PMSF)

K.

(nM)

(nM)

189 ± 73

S.A.
EDso

Tail-Flick
EDso

( mol/k )

( mol/k )

nd

43.7

61.4

1860 ± 300

nd

49.5

72.9

118 ± 29

1410 ± 470

37.5

148.2

> 10,000

nd

> 167

> 167

1150 ± 300

nd

20.7

25.4

H
5

CR-N�OH
H

6

7

8

9

R-�OH

#
�-o-�

R-N

r

\

R-N-

NH2

0

\

j

��
0
1

R-N
0
\._I

'arachidonyI

Br
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Table 3. Comparison of pharmacological potency and receptor affinities of anandamide
analogs with substitutions for hydroxyl.

Structure

Compound

10

II

�

R-N

K (PMSF)

�iS-NH2
II

0

RJ�-0
H

12

R-t�

K

S.A.

(nM)

(nM)

ED so

163 ± 56

Tail-Flick
EDso

( mol/k )

( mol/k )

250 ± 70

44.6

142.4

400 ± l lO

687 ± 107

23

74.1

8.6 ± I.I

2130 ± 460

57.2

190

1820 ± 280

nd

186.1

> 276

H

13

l�OCH3

R-N
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Table 4. Comparison of pharmacological potency and receptor affinities of alkylated
anandamide analogs.
Structure
Compound
K (PMSF)
K;
S.A.
Tail-Flick
(nM)

(nM)

ED so

( mol/k )

EDso

(

ol/k )

�00

14

137 ± 13

87 ± 18

14.1

62.8

5.7 ± 12.1

15 ± 6

13.2

19.3

47 ± 2

41 ± 3

30.5

49.6

53 ± 11

137 ± 20

20.4

23.5

5030 ± 760

nd

> 152

> 152

461 ± 42

285 ± 58

18%@ 157

64.8

4980 ± 376 5240 ± 2025

98.3

32%@ 164

2330 ± 387 2250 ± 800

103

39%@ 160

0

��

F

15
0

OH
�

16
0

�OH

17
0
��H

18

0

19

�

20

d�

21

0

�/yOO

0

)-

�OH

22

�·

23

�'"

5420 ± 1450

> 10,000

0%@ 149

32%@ 149

> 10,000

> 10,000

4%@ 242

30%@ 242
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results resembling anandamide: a higher Ki in the absence of PMSF. Also, this compound
had an affinity 10 times greater than that of anandarnide in the presence of PMSF. An
analog with a methoxy substitution (compound 13) had very low receptor affinity.
In the final series of analogs (Table 4), methyl derivatives were prepared with the
intention of sterically interfering with binding to metabolic enzymes. These analogs, with
the exception of compound 18 (isopropyl at carbon 2), produced Ki's similar to
anandamide in the presence and absence of PMSF. The affinity of compound 17
(methylation at carbon 2) in the absence of PMSF was 2 times lower than anandarnide in
the presence of PMSF, yet compound 17 still had a higher affinity than many of the
analogs. Compound 15, possessing methylation at carbon 2 and a fluorine substitution for
the hydroxyl group, had high affinity with and importantly without PMSF. A previously
discussed fluorine analog (compound 12) had a low Ki only with PMSF, supporting the
idea that methylation at carbon 2 interferes with metabolism in this in vitro system.
Insertion of an ethyl group at carbon 2 (compound 19) reduced the affinity of the analog in
the presence of PMSF, compared to anandamide. Modest differences in binding were
obtained in the absence of PMSF. However, unlike anandarnide, the compound displayed
slightly higher affinity without PMSF. Addition of an isopropyl group at carbon 2
(compound 18) greatly reduced affinity regardless of whether PMSF was present. Two
analogs were made in which the nitrogen was methylated. Compound 20 (methylation at
nitrogen) and compound 21 (methylations at nitrogen and carbon 2) had low affinities in
the presence and absence of PMSF.
One of the criteria in establishing the existence of a receptor is proving
enantioselectivity. A pair of enantiomers therefore were prepared with the intention of
demonstrating enantioselectivity of an anandamide-Iike compound for the cannabinoid
receptor. Recently, Abadji et al. (1994) demonstrated that (R)-( +)-arachidonyl- l '
hydroxy-2'-propylamide bound to the cannabinoid receptor with and without PMSF and
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produced cannabimimetic activity in vivo. Compounds 22 and 23 (R- and S-forms,
respectively) are l '-isobutyl analogs of anandamide. Both compounds possessed a Ki of>
10,000 nM in the absence of PMSF. Any compound with a Ki of greater than 10, 000 nM
is generally found to be pharmacologically inactive, as is demonstrated here. With the
inclusion of PMSF, the R-form bound with weak affinity, and the S-form was inactive.

Behavioral studies. The second objective of this study was to evaluate the
analogs in two behavioral assays that assess cannabimimetic activity. Following an i.v.
injection, the dose responsiveness of anandamide and anandamide analogs on spontaneous
activity and production of antinociception was measured. From these data, EDso values
were calculated for each compound. The EDso of anandamide was 5 0.3 µmol/kg for the
hypomotility assay and 17.4 µmol/kg for the antinociception assay (Smith et al., 1994).
Compounds 1 and 2 were not potent in producing either hypomotility or
antinociception, which was consistent with their low affinity for the receptor. Saturation of
anandamide resulted in an analog (compound 3) that had the same EDso as anandamide for
the spontaneous activity assay, yet it produced antinociception only at very high doses.
Substitution of the hydroxyl group with a fluorine atom combined with complete saturation
(compound 4) was more potent than anandamide for both tests.
Increasing the chain length for the N-substituent (compounds 5 and 6) and
replacing the ethanolamide with a sulfonamide group (compound 7) reduced potencies for
antinociception without changing EDso values in the spontaneous activity assay_
Compound 8 (bromobenzenesulfonamide) did not bind to the receptor, and it did not
produce hypomotility and antinociception. An EDso value was not calculated, since this
compound did not produce a 5 0 % effect. Therefore, the results for compound 8 and other
very weak compounds are reported as greater than the highest dose tested (µmol/kg).
Interestingly, an analog with morpholine substitution for ethanolamide (compound 9) was
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more potent than anandamide in reducing spontaneous activity and just as potent in
producing antinociception, yet this compound had rather low receptor affinity.
The hydroxyl constituent of the ethanolamide moiety was replaced with four
different functional groups.

Compounds 10 and 12 (sulfonamide and fluorine

substitutions, respectively) were similar in potency to anandamide in the spontaneous
activity test, but were 10 times less potent in the tail-flick assay (EDso > 140). Phenoxy
substitution produced compound 11 that was more potent than anandamide in depressing
locomotor activity and approximately five times less potent in producing antinociception.
Compound 13 (methoxy substitution) was inactive, a finding consistent with its very low
binding affinity.
The l' methylated analog (compound 14) was four times more potent in the
spontaneous activity test, but the compound was not as potent as anandamide in the tail
flick assay. Methylation at carbon 2 (compound 17) yielded an analog that was more
potent than anandamide in producing hypomotility and just as potent in producing
antinociception. Similar results were obtained for compound 15 in which the hydroxyl
group was replaced with a fluorine molecule. Compound 16 (dimethyl at carbon 2) was
slightly more potent than anandamide for the spontaneous activity assay and less potent in
the tail-flick test. An isopropyl derivative (compound 18) was inactive in both behavioral
assays. Compound 19 was not as potent as anandamide in the tail-flick assay and
produced little hypomotility. An EDso value could not be calculated for compound 19 in
the spontaneous activity assay since a statistically significant maximal possible effect was
not obtained. Compounds 20 and 21 (methylation at nitrogen and methylations at nitrogen
and carbon 2) produced little or no activity in the spontaneous activity and antinociception
assays. The pair of enantiomers (compounds 22 and 23) neither produced a reduction in
locomotor activity nor generated more than 32% effect in the tail-flick assay.
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Linear correlations were evaluated between binding affinities (log Ki) and in vivo
potencies (Figure 7). Spearman rank order statistics also were perfo1med between the data.
Compounds 3 and 4 were not included in the correlations since binding studies could not
be performed with these insoluble analogs. Linear correlations between Jog SA and log Ki
resulted in a correlation coefficient of 0.68 (Figure 7A), and they were statistically
significant in the Spearman correlation test (P < 0.05, two-tailed). When log TF and log
Ki were compared, a lower linear correlation resulted (r = 0.51), and correlations were not
statistically significant (Figure 7B). All analogs were included when comparing log SA
and log TF (Figure 7C). A correlation coefficient of 0.72 was obtained which was
statistically significant at the P < O.Ql level (two-tailed).
Time course following i.v. administration for anandamide and
compound 16 (2.2-dimethylarachidonyl-(2'-hydroxyethyl)amide) in the tailflick assay. If a compound is stable without the addition of an enzyme inhibitor in vitro,
then the same compound might have greater stability in vivo. Therefore, a time course
study was performed to determine if one of the compounds stable in the absence of PMSF
would have a longer duration of action than anandamide in vivo. Compound 16 (dimethyl
at carbon 2) was selected since its pharmacological potency and receptor affinity, in the
absence of PMSF, were similar to those of anandamide in the presence of PMSF. Tail
flick latencies were measured at 5, 15, 30 and 60 min following drug administration. As
evident in Figure 8, the time course for compound 16 was parallel to that of anandarnide (5
mg/kg). Therefore, the analog did not appear to be more stable than anandamide in vivo.
Anandamide metabolism in the receptor binding assay. In order to verify
that PMSF prevented metabolism of anandamide rather than altering its inherent binding
affinity, [3H]-anandarnide was incubated with rat brain membrane with the same conditions
as in the receptor binding assay. A similar system has been used to detect a wide range of
prostaglandin metabolites (Dr. Earl Ellis, MCV/VCU, personal communication). In the
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absence of PMSF [3 H]-anandamide was completely converted to [3 H]-arachidonic acid; no
other peak was detected. Inclusion of PMSF protected [ 3 H]-anandamide from metabolism,
as evidenced by the lack of [3H]-arachidonic acid formation.

Discussion
In order to verify that Ll9 -THC and anandamide share a common receptor, SAR
studies were conducted for correlative purposes. Extensive SAR studies have identified a
number of structural features of Ll9 -THC important for receptor affinity and
pharmacological potency (Razdan, 1986; Mechoulam et al., 1987). These areas include the
eleven position of the C ring, the phenolic A ring hydroxyl and the alkyl hydrophobic side
chain attached to the A ring. Little structural similarity exists between anandamide, Ll9THC and CP 55,940, the potent synthetic cannabinoid agonist. Therefore, predicting the
alignment of anandamide with the cannabinoid receptor is difficult. Also, due to structural
and metabolic degradative pathway differences between anandamide and Ll9-THC, identical
results in all pharmacological assays should not be expected.
The observation that receptor binding for anandamide is greatly enhanced in the
presence of PMSF, an amidase inhibitor, led to the reasonable assumption that PMSF
inhibits enzymes that degrade anandamide (Childers, Sexton and Roy, 1994). The
metabolic studies described herein confirmed that PMSF did prevent the conversion of
anandamide to arachidonic acid when incubated with rat brain homogenate. Therefore,
PMSF was included in [ 3 H]-CP 55,940 displacement studies for anandamide and its
analogs. The finding that anandamide's receptor affinity was enhanced several hundred
fold is consistent with these metabolic studies and the previous observations of Childers et
al. (1994). PMSF also exerted a minor influence (a two-fold shift) on CP 55,940's
receptor affinity which is not likely to be metabolic. While the PMSF action on CP 55,940
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binding may lack biological significance, it underscores the importance of making
appropriate corrections when conducting competition studies in the presence of PMSF.
The identification of anandamide analogs with similar affinities in the presence and absence
of PMSF indicates that the binding assays can be a useful tool for delineating between
metabolically unstable and stable analogs.
Cannabinoids produce a wide variety of pharmacological properties in different
animal species. A tetrad of behavioral tests in the mouse, including antinociception,
depression of spontaneous activity, catalepsy and reduction in body temperature, have
proven to be highly predictive of cannabimimetic activity (Martin et al., 1981). In addition,
the long duration of action of classical cannabinoids makes it possible to measure all four
pharmacological effects in the same animal. For this study, anandamide analogs were
evaluated for their ability to produce antinociception and depression of spontaneous
activity. Since each test composing the cannabinoid tetrad has been shown to correlate with
receptor binding, only two of the assays were selected to evaluate the anandamide analogs
(Compton et al., 1993). As determined by Compton et al. ( 1993) for 60 cannabinoids, the
correlation coefficients between cannabinoid receptor binding and hypomotility production,
antinociception, temperature reduction and catalepsy were, respectively, 0.91, 0.90, 0.89
and 0.85. In addition, the rapid onset of action of anandamide makes it impossible to
measure all four pharmacological effects in the same animal.
This pharmacological evaluation permitted the identification of several sites in the
anandamide structure important for anandamide's binding to the cannabinoid receptor and
potency in the behavioral assays used to assess cannabimimetic activity. The degree of
saturation is critical for receptor affinity and in vivo potency. Either removal of several of
the cis double bonds or addition of a double bond at carbon 17 decreased affinity and
potencies in both behavioral measures. These results are consistent with those of Felder et
al. ( 1993) who noted that the addition of cis double bonds at carbons 3 and 17 drastically
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increased the Ki. They also reported that removal of the double bond at carbon 3 did not
alter receptor affinity. Complete saturation and hydroxyl substitution with a fluorine group
increased potency in the spontaneous activity and tail-flick assays. Although these
alterations are not comprehensive enough to precisely define an active conformation of the
arachidonyl backbone, they demonstrated the importance of its conformation and the
feasibility of restricting the backbone to an active conformation. Another structural feature
of primary importance is the ethanolamide. Increasing the N-substituent chain length by
one or two carbons decreased affinity and antinociceptive potency, but did not produce
higher ED50 values for spontaneous activity. While an N-substituent appears to be critical
for receptor affinity and behavioral potency, a thorough characterization has not been
completed. For example, substitution with a bulky sulfonamide group produced a
compound with equal affinity to the receptor, as compared to anandamide. However,
substitution with an equally bulky bromobenzenesulfonamide inactivated anandamide. As
for the ethanolamide, substitutions for the hydroxyl constituent affected both binding and
behavioral paradigms. Surprisingly, substitution of the hydroxy group with a sulfonamide
only decreased affinity two-fold when compared to anandamide. Yet, substitution with the
much smaller methoxy group produced an analog with low affinity and very little potency
in the behavioral tests.
Although the correlation was not high between receptor affinity and
pharmacological potency, several explanations are possible to explain this result.
Correlations made by Compton et al. (1993), which were higher than the anandamide
correlations, were performed with a larger database of cannabinoids and with a greater
range of structural diversity. With a larger number and wider range of compounds, a
higher correlation might be obtained for anandamide compounds. On the other hand,
anandamide may possess properties unique from other classical cannabinoids which need
to be evaluated further. The possibility also exists that CP 55,940 and anandamide are
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labeling different receptor subtypes; however, there is no direct evidence for receptor
subtypes in brain at present.
One also should not ignore the role that differences in pharmacokinetics and
metabolism may play between in vitro and in vivo assays. It is interesting that the
correlation between the two pharmacological assays was higher than between either assay
and receptor binding. One possible explanation for the discrepancy between in vivo and in

vitro data is that the pharmacokinetics may vary for each analog. Obviously, it is not
feasible to establish the pharmacokinetics of every analog in an SAR study. Also,
pharmacological differences may exist between in vitro and in vivo experimental
conditions. For in vivo experiments, a rapid time course is used and the behavioral effects
produced by anandamide and the analogs are measured soon after drug administration. In
the receptor binding assay, however, a longer time course, or incubation period, was
selected. Additionally, in the in vitro assay, drugs are exposed to a small amount of brain
tissue; whereas, in vivo experiments result in drug exposure to all tissues of distribution.
As information on the synthesis and metabolism of anandamide emerges, it may be
possible to determine the extent that pharmacokinetics is a contributing factor in SAR
studies.
This SAR study has shown that it is possible to develop high affinity analogs. Two
such analogs (compounds 12 and 15) produced higher binding affinities to the receptor
than anandamide. Both of these analogs contained a fluorine substitution for the 2'hydroxyl; additionally, compound 15 was methylated at carbon 2. Fluorine is an electron
dense atom, and substitution with fluorine might enhance receptor interaction. The
compounds differed in respect to Ki's determined in the absence of PMSF. Compound 12
had a much higher Ki in the absence of PMSF; compound 15 had a Ki lower than
anandamide's with and without PMSF. The increased affinity in the presence of PMSF,
however, did not correlate with increased behavioral potency for both analogs. Compound
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12 had the same potency as anandamide for the spontaneous activity test, yet this analog
had low potency in producing antinociception. At this point, reconciling the difference
between binding affinity and potency is not possible. Further synthesis of similar high
affinity analogs might lead to the development of compounds more stable and potent than
anandamide. Potent and stable analogs would in turn facilitate studying the role of
anandamide in in vitro and in vivo systems.
Methylations were made at several sites on the anandamide backbone in the hopes
of blocking enzyme metabolism. The presence of bulky groups near the site of enzymatic
cleavage produces steric hindrance. It is well known that hydrolysis of either peptides or
esters is inhibited with the addition of increasingly larger alkyl groups. Therefore, a series
of anandamide derivatives were prepared with alkyl groups at either the nitrogen, I', 2
carbon or a combination of alkylations. By alkylating these sites, we postulated that the
amidase activity would be inhibited, and the resulting compounds would have increased
metabolic stability. PMSF was shown to have little influence on the binding affinities of
several of the methylated compounds. Thus, one would expect these compounds to be
active in the behavioral assays and have a longer duration of action. These compounds
were more potent than anandamide in depressing spontaneous activity. Their EDso's for
SA and TF, with the exception of one compound, were similar to that of anandamide.
When the time courses for anandamide and one of the methylated derivatives were
compared, parallel time courses resulted. However, a semilog plot suggested a longer half
life with the methylated compound. Therefore, predicting the stability of analogs in vivo
based upon their sensitivity to PMSF should be done cautiously until there is a clearer
understanding of the role that methylation is playing in receptor binding.
Receptor affinity and potency in the behavioral assays were reduced with the
addition of an ethyl group at carbon 2, and substitution with an isopropyl group at the same
position caused a 10-fold decrease in affinity and almost complete inactivation of
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pharmacological activity. Thus, as alkyl groups of increasing bulkiness were added to
carbon 2, interaction with the receptor was decreased. A size restriction therefore exists for
this site with alkyl chains composed of two or more carbons presenting a steric hindrance
and preventing optimal receptor interaction.
Additional evidence for steric hindrance due to larger alkyl chains was demonstrated
for the carbon l' site. A methylation at carbon l' yielded an analog stable both in the
presence and, importantly, absence of PMSF. This analog had the same affinity as
anandamide for the cannabinoid receptor and also was pharmacologically active. When an
isobutyl group was added at the l' carbon both the R- and S- forms of the compound did
not bind in the absence of PMSF, and only the R-form bound with low affinity in the
presence of the enzyme inhibitor. Also, both analogs had very low pharmacological
activity. For both the l' and 2 carbons, receptor binding and behavioral activity depended
upon the size of the alkyl group substituted at these sites. Addition of a single carbon
produced analogs that were resistant to enzymatic degradation and, therefore, stable
without PMSF. Substitution with larger groups also increased stability; however, these
alkylations also reduced affinity and activity in the behavioral tests.
To further explore the role of methylation and its influence upon stability of the
compounds, two compounds were synthesized with methylations at the nitrogen of
anandamide. Nitrogen methylation dramatically reduced affinity and pharmacological
activity in the tail-flick assay, and no difference existed in binding with and without PMSF.
Similar results were obtained for a compound methylated at both the nitrogen and carbon 2.
The decreased activity of these N-methylated compounds might be due to disruption of a
hydrogen bonding process at the receptor active site, as has been suggested for the proton
in the phenolic hydroxyl of �9-THC (Semus and Martin, 1990). Thus, addition of a
methyl group at the nitrogen prevents proper alignment and binding to the receptor.

85
In summary, these results indicated several areas of the structure which are
important for receptor binding and behavioral potency. Alterations in the number of double
bonds in the arachidonyl moiety, changes in the N-substituent, substitutions for the
hydroxyl group and methylation at carbons adjacent to the nitrogen all influenced receptor
affinity and pharmacological potency. Correlations between binding and pharmacological
data were greatest when the analogs were either very potent or inactive. The greatest
discrepancies existed between binding and behavioral data when the compounds possessed
moderate binding affinity. This study clearly shows that stable and potent cannabinoid
analogs can be developed from anandamide.
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III.

An Autoradiographic Comparison of Anandamide, CP 55,940
and SR 141716A Binding in Rat Brain

Introduction
Following the discovery of the cannabinoid receptor in brain tissue,
autoradiographic experiments were performed to localize the receptor in brain.
Autoradiography of cannabinoid receptors from several mammalian species, including
human, reveals a conserved and unique pattern of distribution (Herkenham et al., 1990).
Binding was most dense in the outflow nuclei of the basal ganglia (the substantia nigra pars
reticulata and globus pallidus), the hippocampus and the cerebellum. The high densities of
receptors in the forebrain and the cerebellum explain the effects of cannabinoids on
cognition and movement. High levels in the hippocampus provide a role for these
receptors in cannabinoid impairment of memory. Sparse densities in the brainstem areas
controlling cardiovascular and respiratory functions would explain why high doses of
marijuana are not lethal. The distribution of cannabinoid receptors in rat brain also was
determined with the aminoalkylindole [3H]-WIN 55,212-2 and [3H]-11-0H-L\9-THC
DMH (Jansen et al., 1992; Thomas, Wei and Martin, 1992). Binding distribution was
very similar between [3H]-CP 55,940, [3H]-WIN 55,212-2 and [3H]- l l -OH-L\9-THC
DMH confirming that these structurally diverse compounds bind to the same receptor.
The pattern of distribution of cannabinoid binding is consistent with data from in
situ hybridization studies (Matsuda et al., 1990).

High levels of mRNA in the

hippocampus were found in granule cells of the dentate gyrus and in cells in the pyramidal
and molecular layers. Expression of message for the cannabinoid receptor was also high in
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cells within the superficial and deep layers of the cerebral cortex and amygdala. The pattern
of distribution is consistent with in situ hybridization data using oligonucleotide probes
complementary to rat cannabinoid receptor cDNA (Mailleux and Vanderhaegen, 1992). In
the hippocampus, high levels of mRNA for the cannabinoid receptor were found in granule
cells of the dentate gyrus and in cells of the pyramidal and molecular layers of the
hippocampus. Message for the receptor was also prevalent within the superficial and deep
layers of the cerebral cortex and amygdala. In the human brain the distribution of the
mRNA encoding for the cannabinoid receptor also has been studied using in situ
histochemistry and oligonucleotide probes (Mailleux, Parmentier and Vanderhaegen,
1992). Microscopically, positive neurons were found in layers II-III and V-VI of the
cerebral cortex, and in the hilus and the dendritic layers of the dentate gyms and Ammon's
horn of the hippocampus. Macroscopically, a small hybridization signal was found
throughout all layers of the cortex, in the pyramidal cell layer of the hippocampus, in the
caudate and putamen and in the granular and molecular layers of the cerebellum.
Binding experiments dealing with the fine neuronal localization of CB I receptors in
the rat basal ganglia indicate that the receptors are not localized on dopamine cell bodies or
terminals (Herkenham et al., 1991 b). Cannabinoid receptors in the basal ganglia are
localized to striatal neurons, with very dense localization to the axons and terminals in the
globus pallidus, entopeduncular nucleus and substantia nigra pars reticulata. This
localization implies that the facilitation of cannabinoids upon nigrostriatal dopamine
function might involve indirect, local and/or distal neuronal circuits. Within the basal
ganglia, cannabinoid receptors occur both pre- and postsynaptically. In the cerebellum,
cannabinoid receptors are neuronally localized to granule cell axons in the molecular layer
(Herkenham et al., 1991a).
In addition to ti9-THC, bicyclic compounds, dimethylheptyl analogs of THC and
arninoalkylindoles, anandamide and SR 141716A have been added to the list of stmcturally
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diverse compounds that bind to the cannabinoid receptor. Although anandamide produces
many of the same effects as other psychoactive cannabinoids, differences do exist.
Comparison between anandamide and ,:19-THC revealed that anandamide was 4- to 20-fold
less potent and had a shorter duration of action than ,:19-THC (Smith et al., 1994).
Anandamide also acted as a partial agonist at the N-type calcium channels (Mackie, Devane
and H ille, 1993). Anandamide produces antinociception like other cannabinoids, but
anandamide is not active when administered i.c.v. (Smith et al., 1994). Also, unlike other
cannabinoids, anandamide's antinociception is not blocked by the kappa antagonist norBNI (Smith et al., 1994).
The structure-activity relationship studies in the first part of this dissertation
provided evidence that anandamide was binding to the cannabinoid receptor and producing
pharmacological effects in mice, such as depression of spontaneous locomotor activity and
generation of antinociception. The next objective in this dissertation was to determine
whether anandamide might interact differently with receptors in some brain areas by using
the technique of receptor autoradiography. Since anandamide does not have high affinity
for the cannabinoid .receptor, in comparison to other synthetic high-affinity THC analogs,
[3H]-anandamide was not used directly to Habel receptors. Performing autoradiography
with compounds possessing weak affinity to a receptor introduces many technical
problems. Weak ligands diffuse from the receptor, and the resulting autoradiogram is not
clear. Fuzzy images cannot be accurately analyzed. To avoid this problem, [3H]-CP
55,940 was selected. In these experiments anandamide (unlabeled) competed with [3H]
CP 55,940 for binding to the cannabinoid receptor. The autoradiograms thus depict
anandamide's displacement of labeled CP 55,940. The recent discovery of the cannabinoid
antagonist SR 141716A also provided the opportunity to study the binding of this

89
compound. SR 141716A was not available in a tritiated form; therefore, autoradiograms of
SR 141716A also show its displacement of labeled CP 55,940.
The purpose of the autoradiographic experiments was to determine if differences
exist between the cannabinoid receptor population which binds CP 55,940, SR 141716A
and anandamide. The technique of autoradiography was used to quantitatively compare
cannabinoid receptor affinities, binding patterns and densities of anandamide, CP 55,940
and SR 141716A in different brain regions. If anandamide, CP 55,940 and SR 141716A
are binding to the same cannabinoid receptor (CB 1) in the brain, then the binding
localization should be the same in different brain regions for all three compounds.
Differences in binding densities between regions for the three compounds might suggest
that a receptor subtype for the central cannabinoid receptor exists. Furthermore, a second
objective was to determine cannabinoid receptor affinities for anandamide, SR 141716A
and CP 55,940 and compare the affinities for each compound between brain regions.
Differences in affinities would indicate that a particular drug was binding to a brain region
in a different manner than to cannabinoid receptors in other regions. Binding displacement
curves from selected brain regions also were analyzed for parallelism for each compound.

Methods
Animals. Male Sprague-Dawley rats (150 - 200 g) from Harlan Laboratories
were maintained on a 14: 10 hr light/dark schedule and freely received food and water.
Chemicals. [3H]-CP 55,940 was purchased from DuPont NEN (Wilmington,
DE). CP 55,940 was a gift from Dr. L. Melvin of Pfizer Inc., Central Research Division
(Groton, CT), and anandamide was kindly provided by Dr. Raj K. Razdan of Organix Inc.
(Woburn, MA). Both compounds were prepared as 1 mg/ml stock solutions in absolute
ethanol and stored at -20 °C. SR 141716A was obtained from Pfizer Inc. (Groton, CT),
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and prepared as a 1 mg/ml solution in absolute ethanol. PMSF was dissolved in absolute
ethanol as a 20 mg/ml stock solution.
Tissue Preparation. Following decapitation, rat brains were quickly removed
and frozen in 2-methylbutane (-50 °C). The brains were embedded in M-1 embedding
matrix and stored at -70 °C until sectioning. Brains were mounted onto cryostat chucks
with TFM tissue freezing medium. Consecutive coronal brain sections (16 µm) were thawmounted onto slides coated with 0.5% gelatin and 0.05% chromium potassium sulfate.
Sections were made at the stereotaxic coordinates 1.2 mm from bregma, 0.48 mm from
bregma, -5.2 mm from bregma and -12.8 mm from bregma (Paxinos and Watson, 1986).
Sections were stored desiccated at -70 °C prior to use in binding assays.
In situ Cannabinoid Bindin2 Assays.

Assay conditions for cannabinoid

binding have been described previously (Herkenham et al., 199 l c).

Saturation

experiments were first performed to determine the l<{! of [3H]-CP 55,940. This value then
was compared to values reported in the literature. Coronal sections containing primarily
frontal cortex and caudate-putamen (1.2 mm from bregma) were used for Scatchard
analysis. Slides were allowed to return to room temperature and incubated for 2 hr in slide
mailers at 37 °C in reaction buffer (50 mM Tris-HCI with 5% BSA, pH 7.4) Total binding
was determined with seven concentrations of [3H]-CP 55,940 (1.13, 2.3, 4.5, 7.5, 15,
22.5 and 30 nM); nonspecific binding mailers additionally contained 1 µM CP 55,940
(non-radiolabeled). Saturation experiments were also performed with 50 µM PMSF in the
incubation buffer. Following incubation, slides were washed for 4 hr at O °C in 50 mM
Tris-HCI with 1% BSA (pH 7.4). Sections were scraped from the slides with Whatman
GF/C filters. The filters were placed in scintillation vials, and the tissue was solubilized
overnight with 1.0 ml of TS-2. Samples were acidified with 10 µl of glacial acetic acid and
counted by liquid scintillation spectrometry. Transformation of the data and calculation of
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Kl values was accomplished using the LIGAND computer software developed by Munson
and Rodbard (Munson and Rodbard, 1980) as supplied by Biosoft Inc. (Cambridge,
U.K.).
Competition for f3H]-CP 55,940 Bindini:. Due to the reported instability
of anandamide (Childers, Sexton and Roy, 1994; Deutsch and Chin, 1993), optimal
binding conditions were first determined in the presence and absence of the enzyme
inhibitor PMSF. In the competition experiments, reaction buffers, incubation temperatures
and times were identical to the in situ binding assay described above. Sections were made
from 0.48 mm from bregma, -5.2 from bregma and -12.8 mm from bregma. For CP
55,940, SR 141716A and anandamide, nonspecific binding was determined using 10 µM
CP 55,940, and total binding was determined for 10 nM [3H]-CP 55,940 (approximately
40% receptor occupation). Eight concentrations of CP 55,940 ranging from 0.1 to 300 nM
were assayed; concentrations of anandamide ranged from 0.0 I to 10 µM, and
concentrations of SR 141716A were 0.001 to 10 µM. Each experiment was conducted in
at least triplicate. For anandamide displacement assays, additional experiments were
performed either with 50 µM PMSF in the incubation buffer or with sections pretreated for
30 min in a buffer containing 50 µM PMSF prior to exposure of 50 µM PMSF in the
incubation buffer. Anandamide sections were wiped from the slides, solubilized and
counted. Optimal conditions for anandamide competition experiments occurred when
sections were pretreated for 30 min with PMSF and exposed to PMSF in the incubation
buffer.
[3H]-CP 55.940 Autoradioi:raphy. Following the wash, slides were rapidly
dried with a stream of cool air and stored in a desiccator overnight at 4 °C. Sections were
apposed to tritium-sensitive film with [3H]-microscales for three weeks before developing
with a D-19 developer. Developed films were analyzed using the NIH Image 1.49
program. Levels of transmittance were converted to dpm/mg protein using a polynominal
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curve fit of the standards. Brain structures were outlined, and optical density in each area
was measured. Curve-fitting of the displacement data and determination of Ki and Bmax
values for anandamide, CP 55,940 and SR 141716A were done using EBDA software. Ki
and Bmax values for anandamide in the substantia nigra and the molecular layer of the
cerebellum were determined from autoradiograms apposed to film for one week.

Statistical Analysis. Significant differences between Ki values were
determined using the ANOVA analysis (Scheffe post-hoc analysis). To determine if curves
were parallel, data from a representative displacement curve from each brain area for
anandamide, SR 141716A and CP 55,940 were analyzed using the ALLFIT curve-fitting
program. Bmax values were compared by linear correlations for Anandamide and CP
55,940 and SR 141716A and CP 55,940.

Results
Cannabinoid receptor affinity (Kct ) was determined for CP 55,940 and expressed as
a Kct value. Saturation experiments were performed both in the presence and absence of the
enzyme inhibitor PMSF. Without PMSF a Kct value of 15.3

±

1.2 nM (n = 5) was

calculated, which correlated with value of 15 ± 3 nM obtained by Herkenham et al. (1990).
In the presence of PMSF a Kct value of 12.3 ± 2.1 nM (n = 3) resulted, which is not
statistically different from the Ki value obtained without PMSF. The presence of PMSF
did not influence affinity to the cannabinoid receptor. Thus, all Ki's were calculated using
the Kct value of 15.3 nM.
Since in the first part of this dissertation, it was determined that anandamide is
susceptible to enzymatic cleavage, conditions were established for determining optimized
receptor binding with anandamide in autoradiography experiments were established.
Without inclusion of PMSF a Ki of 8030 ± 1110 nM (n = 3) resulted. PMSF (50 µM)
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Total Binding

Nonspecific Binding
Figure 9. Autoradiogram of total and nonspecific binding of [3H]-CP 55,940 to coronal
sections of rat brain.
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Frontal Cortex

Parietal Cortex

Medial Caudate-Putamen

Lateral Caudate-Putamen

Figure 10. Autoradiogram of [3H]-CP 55,940 binding to a coronal section of rat brain
0.48 mm from bregma.
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Occipital Cortex

Entorhinal Cortex

Dentate Gyrus

CAI

CA3

Substantia Nigra, Reticular

Figure 11. Autoradiogram of [3H]-CP 55,940 binding to a coronal section of rat brain
-5.2 mm from bregma.
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Molecular Layer

Figure 12. Autoradiogram of (3H]-CP 55,940 binding to a coronal section of rat brain
-12.8 mm from bregma.
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SR 141716A (30 nM)

CP 55,940 (3 nM)

Anandamide (300 nM)

Figure 13. [3H]-CP 55,940 displacement by SR 147161A (30 nM), CP 55,940 (3 nM)
and anandamide (300 nM).
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Figure 14. Anandamide, SR 141716A and CP 55,940 displacement of [3H]-CP 55,940 in
the lateral caudate-putamen. The curves are representative displacement curves.
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then was added to the incubation buffer during the 2 hour reaction period. The Ki
decreased to 2320 ± 540 nM (n = 6), but a Ki in this range demonstrates weak receptor
affinity and suggests that anandamide is probably being degraded. Thus, slices were
pretreated for 30 minutes with 50 µM PMSF and exposed to PMSF during the incubation
time. A Ki of 608 ± 210 nM (n = 3) resulted from these assay conditions. These results
indicate that anandamide is degraded without the addition of an enzyme inhibitor.
Therefore, slices were exposed to PMSF before and during incubation for autoradiography
experiments using anandamide.
Levels and patterns of cannabinoid receptor binding ([3H]-CP 55,940) were in
agreement with previously reported data (Herkenham et al., 1991c; Jansen et al., 1992;
Thomas, Wei and Martin, 1992). High levels of binding were found in the substantia nigra
pars reticulata, molecular layer of the cerebellum, dentate gyrus and CA1 and CA3 regions
of Ammon's horn. Moderate levels of cannabinoid receptor binding was observed in all of
the cortical areas and throughout most of the brain. Little binding was found in the
brainstem or the corpus callosum indicating a lack of receptors in these areas.
A qualitative examination of the autoradiographic film demonstrates that only
nonspecific binding results when an excess of unlabeled CP 55,940 ( lµM) is added
(Figure 9). Sections were made at three points in the rat brain. The stereotaxic coordinates
were 0.48 mm, -5.2 mm and -12.8 mm from bregma. At 0.48 mm from bregma
measurements were made in the lateral and medial caudate-putamen and the frontal and
occipital cortices (Figure 10). At -5.2 mm from bregma measurements were made from the
CAI and CA3 regions from Ammon's horn, dentate gyrus, entorhinal and occipital cortices
and substantia nigra (Figure 11). At -12.8 mm from bregma measurements were made
from the molecular layer of the cerebellum (Figure 12).
Also apparent from a visual inspection of the developed brain images, is the
similarity of the displacement patterns for SR 141716A, CP 55,940 and anandamide.
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Table 5. Ki values for anandamide, CP 55,940 and SR 141716A.

Anandamide
Brain Region

K

CP-55,940

K

SR 141716A

K

(nM)

(nM)

(nM)

Entorhinal Cortex
Parietal Cortex
Occipital Cortex
Frontal Cortex

956**
713±7
328±86
661±145

10.2 **
6.7±2.1
17.5±7.8
8.5±0.2

36±4
35±14
34±7
26±10

Medial Caudate-Putarnen
Lateral Caudate-Putamen

566±93
515±68

9.0±2.0
5.3± 1.3

31±8
52±17

Dentate Gyms
CAI
CA3
Substantia Nigra
Molecular Layer of the
Cerebellum

400±72
438±87
489±176
512±169
861±32

8.5±0.7
6.0±0.9
7.4±1.3
7.3±2.9
12.5±4

36±5*
24±3*
38±5*
95±29*
114±19*

*n = 6
**n = 2
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Table 6. Bmax values for anandarnide, CP 55,940 and SR 141716A.

Anandamide CP-55,940
Brain Region

SR 141716A

Bmax

Bmax

Bmax

(pM)

(pM)

(pM)

Entorhinal Cortex
Parietal Cortex
Occipital Cortex
Frontal Cortex

44±7
50±2
59±7
76±11

28±7
34±4
42±7
56±7

48±14
66±6
43±2
94 ±6

M edial Caudate-Putamen
Lateral Caudate-Putamen

108±7
185±33

44±2
109±9

107±13
189±19

Dentate Gyms
CAI
CA3
Substantia Nigra
M olecular Layer of the
Cerebellum

211±13
258±22
771**
209±4
263±44

110±22
151±29
163±33
212±34
250±55

149±16*
147±15*
150±20*
204±35*
248±22*

*n = 6
**n = 2
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Figure 15. Relationship between Bmax values for anandamide, SR 141716A and CP
55,940.
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Figure 13 shows that binding density, qualitatively, appears not to differ between SR
141716A, CP 55,940 and anandamide at 3 0 nM, 3 nM and 3 000 nM, respectively. These
concentrations represent approximately 50 % displacement of [3HJ-CP 55,940.
To quantitate results from autoradiography, measurements were made from the
developed autoradiographic film of selected brain areas, and displacement curves were
constructed. Figure 14 shows representative displacement curves for anandamide, SR
141716A and CP 55,940 in the lateral caudate-putamen. Since anandamide is a weaker
ligand for the cannabinoid receptor, anandamide's displacement curve lies to the right of
CP 55,940's curve. The curve for SR 141716A is to the right of CP 55,940's curve and to
the left of anandamide's curve. SR 141716A has a higher affinity to the cannabinoid
receptor than anandamide and has a lower affinity than CP 55,940. CP 55,940 is more
potent than anandamide and SR 141716A. Similar curves were generated from the other
regions.
Analysis of displacement data by EBDA generated Ki and B max values. Ki values
reflect the receptor affinity of the displacing compound, and Bmax values are a measure of
receptor number or density. Ki values for anandamide, SR 141716A and CP 55,940 from
each brain area are found Table 5. The average Ki value for anandamide in the rat brain
homogenate binding assay in the presence of PMSF was 90 nM, and the average Ki value
for anandamide in the autoradiography experiments was 548 nM. Higher Ki and Kd values
are obtained using in situ binding than in homogenate membrane binding. These
differences are consistent for numerous ligands and probably reflect methodological
differences between the two types of assays (Herkenham et al., 199 l c). Average Ki values
were 9 nM for CP 55,940 and 47 nM for SR 141716A. Binding affinities were analyzed
statistically to determine if differences existed for anandamide's affinity to the central
cannabinoid receptor between different brain regions. Statistical analyses also were
performed for SR 14 1716A and CP 55,940. Binding affinities for anandamide, SR
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141716A and CP 55,940 were not statistically significant between brain areas. The K i for
the entorhinal cortex for anandamide and CP 55,940 were not included in the statistical
analysis since the value was determined from an average of only two experiments. The
cannabinoid receptor had the same affinity for anandamide in all regions analyzed. Binding
affinities for CP 55,940 and SR 141716A also did not differ between brain regions.
A representative displacement curve was selected from each brain region for each
compound. The curves for anandamide, CP 55,940 and SR 141716A were analyzed for
parallelism by the program ALLFIT. All displacement curves for anandamide and CP
55,940 from each brain area were parallel. All displacement curves for SR 141716A,
except for the entorhinal curve, were parallel.
Bmax values for anandamide, CP 55,940 and SR 141716A are summarized in Table
6. Bmax's are listed from low to high based upon the values for CP 55,940. Bmax values
are listed in Table 6 according to areas with lower values (the cortices), areas with moderate
values (the caudate-putamen) and areas with higher values. The molecular layer of the
cerebellum had the highest Bmax for anandamide (with the exception of CA3), CP 55,940
and SR 141716A. For an unknown reason, the Bmax for anandamide in the CA3 region
was extremely high and was calculated from only two assays; therefore, it was not used
when determining correlations between anandamide and CP 55,940. The entorhinal cortex
had the lowest Bmax's for anandamide and CP 55,940. The lowest value for SR 141716A
was in the occipital cortex. To compare densities, linear correlations were made between
CP 55,940 and SR 141716A. Correlations also were made between CP 55,940 and
anandarnide. Good correlation existed when comparing Bmax values for anandamide to the
Bmax values of CP 55,940 (r = 0.89) (Figure 15). A correlation coefficient of 0.92 was
obtained when Bmax values for SR 147161A were compared to Bmax values of CP 55,940.

Discussion
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According to autoradiographic studies, the distribution of the cannabinoid receptor
is heterogeneous in several mammalian species, conserved and neuronally located
(Herkenham et al., 1990; Herkenham et al., 1991b; Herkenham et al., 1991c). The
densest binding occurs in the basal ganglia (substantia nigra pars reticulata, globus
pallidus, entropeduncular nucleus and lateral caudate putamen), and the molecular layer of
the cerebellum. Binding in these regions may explain cannabinoid interference with
movement. Intermediate levels of binding were found in the CA pyramidal cell layers of
the hippocampus, the dentate gyrus and layers I and VI of the cortex. �9-THC disrupts
short-term memory in humans (Chait and Pierri, 1992). Cannabinoid effects on memory
and cognition are consistent with receptor localization in the hippocampus and cortex. The
hippocampus stores memory and codes sensory information. The presence of cannabinoid
receptors in regions associated with mediating brain reward (ventromedial striatum and
nucleus accumbens) suggests an association with dopamine neurons. Sparse levels were
detected in the brainstem, hypothalamus, corpus callosum and the deep cerebellum nuclei.
Low levels of receptors in brainstem areas controlling cardiovascular and respiratory
functions is also consistent with the lack of lethality of marijuana.
The first step in autoradiographic binding, or any receptor binding technique, is to
establish optimum binding conditions. The incubation times, temperature and BSA content
were based upon those of Herkenham et al. (1991). A Scatchard analysis of saturation
experiments using frontal cortex from the rat brain produced a Kct (15.3 nM) that
corresponds to other Kct values in the literature (Herkenham et al., 1991; Thomas et al.,
1992). Since anandamide is degraded in homogenate binding, it also was necessary to
determine optimal binding conditions for anandamide. Consistent results were obtained
when slices were pretreated with PMSF and exposed to PMSF during the reaction
incubation. These results confirm previous reports of anandamide's instability in a
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biological system. Since slices had to be both pretreated and exposed to PMSF during the
entire two hour experiment, this finding suggests that levels of the enzyme that degrade
anandamide are high in the brain. If anandamide is a neurotransmitter, then mechanisms
must exist in the CNS to rapidly remove anandamide and prevent continuous stimulation.
Therefore, one would not expect an endogenous compound to possess great stability.
Development of more stable analogs would eliminate the need of exposing brain tissue to
enzyme inhibitors.

PMSF inhibits a wide variety of enzymes, not just amidases.

Therefore, it was necessary to determine if PMSF produced an effect upon cannabinoid
receptor affinity, as determined from saturation experiments. Unlike the homogenate
receptor binding assay, PMSF did not influence cannabinoid receptor affinity for brain slice
binding. The Kd determined in the presence of PMSF was not statistically different from
the

Kci

obtained in the absence of PMSF. It is unknown why PMSF caused a two-fold

shift in the receptor affinity in the homogenate receptor assay, but the shift is probably due
to methodological differences between slice and homogenate binding.
Once conditions were established, a series of autoradiography experiments were
performed using [3H]-CP 55,940 to determine if anandamide, SR 141716A and CP
55,940 were binding to the same receptor in the brain. Following three weeks of
apposure, the resulting autoradiograms showed the displacement of [3H]-CP 55,940 by
either anandamide, SR 141716A or CP 55,940 in the following brain areas: lateral and
medial caudate-putamen, frontal, occipital, entorhinal and parietal cortices, dentate gyrus,
substantia nigra and the molecular layer of the cerebellum. These areas were selected since
cannabinoids affect the functioning of these regions. Also, they are all large enough so that
a sufficient number of consecutive 16 µm slices can be made. Several of the areas,
including the molecular layer of the cerebellum and the substantia nigra, have very dense
levels of receptors. The dentate gyrus, CA1, CA3 and lateral caudate-putamen also have
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dense receptor populations. The cortical regions have moderate levels of cannabinoid
receptors.
The purpose of this section of the dissertation was to quantitate the binding of
anandamide, SR 141716A and CP 55,940 in selected brain regions.

Extensive

autoradiographic experiments have been performed with CP 55,940 (Herkenham et al.,
1990). However, no such experiments have been performed with anandamide or SR
141716A. Results from these experiments would answer the question of whether CP
55,940, anandamide and SR 141716A were binding to the same receptor in the same
manner. Analysis of measurements made from the developed film produced Ki and Bmax
values. Ki values are a measure of a compound's affinity for a receptor; Bmax values
represent the density of receptors. For anandamide, CP 55,940 and SR 141716A, no
statistical difference existed between their Ki's in different brain regions. The Ki values
from the entorhinal cortex for anandamide and CP 55,940 were not included in the
statistical analysis since they were calculated from just two experiments. Also, Ki values
for the substantia nigra and the molecular layer of the cerebellum were inconsistent when
determined from film apposed for three weeks. Values for these two regions were
therefore determined from film apposed for one week. Since anandamide is a weak ligand,
it is possible that at the lower concentrations in anandamide's displacement curves the
percentage of displacement is less accurate because the amount of displacement is
overshadowed by the high numbers of receptors. If any of these compounds were binding
to a receptor subtype possessing either a higher or lower Ki from the other regions, a
statistical difference would result. No such differences were found for CP 55,940,
anandamide or SR 141716A.
A second objective was to analyze representative curves for parallelism from each
region for anandamide, SR 141716A and CP 55,940. Representative displacement curves
from each brain region for anandamide were analyzed using the statistical program ALLFIT
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to determine if they were parallel. Differences in parallelism would provide evidence that a
compound was interacting with the cannabinoid receptor in a different manner from other
regions. All 11 curves for anandamide were parallel, as were curves for CP 55,940. For
an unknown reason, the entorhinal cortex curve for SR 141716A was not parallel to the
other brain regions analyzed. Thus, these three compounds appear to bind to the CB l
receptor in a similar manner.
Cannabinoid receptor densities (Bmax's) were calculated for each brain region for
anandamide, SR 141716A and CP 55,940. The purpose of calculating Bmax values for
each region was to determine if one compound might bind more or less in one brain area
than in other regions. The relationship between Bmax values for SR 141716A and CP
55,940 and anandamide and CP 55,940 were compared by linear plots of the respective
values, and correlation coefficients were determined. A high correlation was obtained both
when comparing the Bmax values of SR 141716A and anandamide to those of CP 55,940.
These correlations indicate that the three compounds are binding to the same population of
receptors when comparing brain regions.
Several conclusions may be drawn from these results. The lack of difference
between receptor affinity, receptor distribution and parallelism of the displacement curves
indicates that anandamide, SR 141716A and CP 55,940 are binding to the same receptor in
the same manner. No evidence of receptor subtypes in the brain was found.
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IV.

General Discussion

Marijuana is one of the most widely abused drugs throughout the world, yet it also
has great therapeutic potential and has been used for centuries for medicinal purposes. The
psychoactive constituent of marijuana, �9 -THC, produces a myriad of pharmacological
effects in animals and humans. Great progress has been made in the past ten years
regarding our understanding of the mechanism of action of cannabinoids. Cannabinoid
receptors have been characterized both centrally and peripherally, and the distribution of the
central cannabinoid receptor has been mapped throughout the central nervous system. The
cellular mechanism of action of cannabinoids also has been more clearly defined. The
discovery of anandamide as an endogenous ligand for the cannabinoid receptor creates the
possibility of discovering a novel neurochemical system. The actions of cannabinoids and
anandamide can better be elucidated with the recent discovery of an antagonist for the
receptor. These advancements provide powerful tools for future research and should
contribute to the expansion of our knowledge of the cannabinoid field.
These initial in vitro and in vivo experiments provided information that anandamide
produced its effects by interacting with the cannabinoid receptor. Yet, differences do exist
between anandamide and other cannabinoid agonists. Anandamide acted as a partial
agonist at N-type calcium channels, whereas other cannabinoids inhibit N-type channels by
acting as full agonists (Mackie, Devane and Hille 1993). �9 -THC decreased choice
accuracy as the retention time increased in delayed nonmatching to sample memory task
performance; anandamide did not affect memory in the same manner. Anandamide was
less potent than �9 -THC in inhibiting adenylyl cyclase (Vogel et al., 1993) and the
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electrically evoked twitch response of the mouse isolated vas deferens (Devane et al., 1992;
Pertwee et al., 1993). Anandamide was also less potent than �9 -THC in producing
antinociception, hypothermia, depressed locomotor activity and catalepsy. After i.v.
administration anandamide had a shorter duration of action for catalepsy and hypothermia
(Smith et al., 1994). Anandamide differed from �9 -THC in that anandamide produced all
cannabinoid effects after i. t. administration except catalepsy, and that after i.p.
administration the only effect anandamide produced to a significant degree was locomotor
inhibition (Smith et al., 1994). Furthermore, the kappa opioid antagonist, nor-BNI, which
blocks �9-THC-induced antinociception, did not alter antinociception after anandamide
administration (Smith et al., 1994). This lack of antagonism for anandamide provided
evidence for a distinct mechanism of action of anandamide-induced antinociception from
that of �9 -THC. Thus, questions remain as to whether anandamide produces all of its
central effects through the CB I receptor.
One of the purposes of this dissertation was to examine structure-activity
relationships in anandamide analogs. In order to verify that �9 -THC and anandamide share
a common receptor, SAR studies were conducted for correlative purposes. Extensive SAR
studies with �9 -THC have resulted in a three-point receptor attachment theory. �9-THC is
believed to interact with cannabinoid receptors through a free phenolic hydroxyl group, an
appropriate substituent at the C9 position, and a lipophilic side chain (Binder et al., 1984;
Howlett et al., 1988). SAR have also helped to develop more potent analogs of the
psychoactive constituents of marijuana, such as the bicyclic compounds and dimethylheptyl
derivatives. Although SAR studies suggested that cannabinoids produced their effects
through a specific receptor, initial binding studies conducted with [3H]-�9 -THC were not
successful because �9 -THC does not possess high affinity for the receptor and is highly
lipophilic. The development of potent cannabinoids like CP 55,940 allowed for the
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characterization of the cannabinoid receptor. [3H]-CP 55,940 also was used to localize the
cannabinoid receptor in rat brain slices (Herkenham et al., 1991).
The shorter duration of action of anandamide could arise from dissimilarities in
metabolism. The likelihood that metabolism plays a role in the actions of anandamide was
raised with reports that PMSF, an enzyme inhibitor, interfered with the degradation of
anandamide (Childers et al., 1993; Deutsch and Chin, 1993). PMSF did not inhibit a
synthase enzyme which catalyzes the formation of anandamide from arachidonic acid and
ethanolamine. Initial competition binding studies with [3H]-WIN 55,212-2 suggested that
anandamide had low affinity for the receptor (Childers, Sexton and Roy, 1994). These
researchers discovered that the addition of PMSF to the membrane preparation dramatically
enhanced anandamide's affinity for the receptor. Subsequent binding studies performed in
our laboratory supported this finding in that the binding affinity of anandamide was
enhanced several hundred fold with the addition of PMSF (Smith et al., 1994). Since the
development of more potent analogs of i'.l9-THC greatly facilitated studying the
pharmacological and physiological role of cannabinoids, a second objective was to develop
metabolically stable analogs of anandamide. Fully investigating the mechanism of action of
metabolically unstable and weak compounds is difficult.
To accomplish the two main objectives of understanding structural requirements
important for anandamide's interaction with the central cannabinoid receptor and
developing metabolically stable derivatives of anandamide, a series of analogs was
synthesized with alterations to the main structural features of anandamide. Anandamide is
composed of an arachidonyl group linked to ethanolamine through an amide bond. Double
bonds are located at carbons 6, 8, 10 and 13, and a hydroxyl group is located at carbon 2'.
Changes were made in the level of saturation of anandamide; substitutions were made for
the ethanolamide and hydroxyl groups, and alkylations were made at certain sites of
anandamide. The analogs were evaluated for their ability to displace [3H]-CP 55,940 in a

112
filtration binding assay using rat brain membranes in the presence and absence of the
PMSF.

Behavioral activity was assessed by the ability of the analogs to produce

hypomotility and antinociception in mice. The receptor affinities of anandamide analogs
were correlated with in vivo pharmacological potencies in the hypomotility and
antinociception assays and compared to those of anandamide. Thus, these results would
provide information about the structural requirements important for anandamide's
interaction with the cannabinoid receptor.
Results from these studies allowed for the identification of sites in anandamide's
structure which were important for anandamide's interaction with the cannabinoid receptor
and potency in the behavioral assays used to assess biological activity. The first series of
analogs had alterations in the level of saturation. Removal of all of the cis double bonds
with the exception of the double bond located at C 10 or addition of another cis double bond
at C 17 produced compounds with lower affinity and weaker potency. Complete saturation
obliterated antinociception. Although these changes are not comprehensive, conclusions
may be drawn that the level of saturation is critical to anandamide's interaction with the
cannabinoid receptor. The purpose of the double bonds is probably to introduce rigidity
and restrict the movement of carbon tail. The double bonds force the carbon chain to
assume a more restricted form. The arrangement of the double bonds more than likely
restricts the backbone of anandamide to an active conformation and allows proper
alignment of anandamide with the cannabinoid receptor.
One of the features of �9-THC important to receptor affinity and pharmacological
potency is the phenolic A ring hydroxyl. One may speculate that the hydroxyl group of
anandamide corresponds to the hydroxyl group of �9-THC. To test this hypothesis,
several analogs were made with substitutions of the hydroxyl group. Substitutions with
two bulky groups (sulfonamide and phenoxy) produced compounds that bound to the
receptor with higher affinities than anandamide with and without PMSF; the difference in
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affinities without PMSF was not as great as anandamide's affinity without PMSF. Yet,
these substitutions interfered with the ability to produce antinociception. Although
substitution with bulky groups produced weaker compounds, substitution with a much
smaller methoxy group produced a basically inactive compound. The most interesting
substitution involved a compound with a fluorine group; this analog had a IO-fold higher
affinity to the receptor, but only in the presence of PMSF. Substitution of the ethanolamide
group with bulkier substituents yielded analogs that did not bind as well to the receptor.
The length of the chain attached to the nitrogen was important; increasing this chain
decreased affinity and potency in producing antinociception. Based upon these results, one
may conclude that the hydroxy group interacts with the receptor. Addition of bulky groups
probably interfered with proper receptor alignment. Thus, the resulting analogs were not
as effective agonists, and, consequently, they had reduced affinity and potency in the
behavioral assays. The fluorine substitution actually produced a compound that bound
better to the receptor, but it was not metabolically stable. Since fluorine is an electrondense atom, it may allow better interaction with the active site of the cannabinoid receptor.
Since the enzyme that metabolizes anandamide acts by cleaving the amide bond,
compounds were synthesized that might block the access of the enzyme to this site.
Methylations at carbons 2 and l' and a dimethylation at carbon 2 presumably enhanced the
stability of the anandamide analogs as evidenced by an increase in their receptor affinity in
the absence of PMSF. Thus, one may reason that the methylations in these compounds
provided resistance to enzymatic degradation. Receptor affinity appears to be least affected
by the substitution at carbon 2 versus carbon l '. When larger and bulkier alkyl groups
were added to these sites, receptor interaction decreased. Furthermore, replacement of the
hydrogen attached to the nitrogen with a methyl group decreased both affinity and potency.
The methyl group at the nitrogen prevented proper receptor alignment. Stable compounds
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can be produced by methylating the anandamide structure, but a restriction on the size and
placement of the attached alkyl groups exists.
The most promising analog in this study was a compound methylated at carbon 2
with a fluorine substitution for the hydroxy. The binding affinity of this analog was greater
than anandamide in both the presence and, importantly, absence of PMSF.

The

combination of methylation and fluorine substitution produced a compound that appeared to
be more stable. It also was more potent than anandamide in reducing spontaneous activity
and had the same potency in producing antinociception. This compound provides an
excellent model upon which to modify and synthesize compounds that have greater affinity
and in vivo potency than anandamide.
It is not clear why the potency and receptor affinity of these methylated analogs
were not enhanced in a comparable fashion. Anandamide is presumed to be rapidly
degraded in vivo because of its relatively low potency. However, there are numerous other
pharmacokinetic factors, coupled with its relatively low receptor affinity, which could
account for its low in vivo activity. Only direct pharmacokinetic studies will answer these
questions. It should be noted that �9-THC and anandamide have time courses in tail-flick
(only) which are not too dissimilar when equi-active doses are administered (Smith et al.,
1994). Anandamide may be vulnerable to enzymatic degradation in the receptor binding
assay because of the long incubation period. Furthermore, anandamide may differ in
regards to its time course.
One of the objectives of this study was to correlate receptor affinity and
pharmacological potency for the analogs. A good correlation exists for cannabinoids
regarding their receptor affinities and pharmacological potencies (Compton et al., 1993).
Several possible explanations exist to explain why correlation was not high for anandamide
analogs. Previous correlation studies were performed with a much greater number of
compounds possessing a wider range of potencies and affinities. On the other hand,
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anandamide might be binding to different receptor subtypes, though there is no direct
evidence for subtypes in the CNS. Although great care was taken to minimize differences
in the fate of these compounds in the in vivo and in vitro conditions, it is likely that
solubility factors, metabolism and tissue distribution were not the same for all of these
compunds.
Several very recent papers have explored the structure-activity relationships of
anandamide and provide support for the conclusions drawn in this dissertation. Edgemond
et al. (1994) investigated the role of the hydroxyl group in the binding of anandarnide using
two analogs. For one analog the alkyl hydroxyl group was replaced with a hydroxyphenyl
group, and the ethanolamide group of the second analog was replaced with a
hydroxyphenyl group. Both compounds had weaker affinity for the CB I receptor than
anandamide. Neither analog was a substrate for PMSF, which provides evidence that the
amidase is selective for fatty acid ethanolamides. Recently, Pinto et al. (1994) studied the
structure-activity requirements for a series of novel amides and rigid hairpin conformations
typified by N-(2-hydroxyethyl)prostaglandin amides. Extending the hydroxyalkyl group
by one carbon increased affinity to the CB I receptor by an order magnitude. Substituting
the hydroxyalkyl moiety with a propyl group increased affinity by five-fold. They
concluded that the bulk and length of the moiety attached to arachidonic acid are more
important determinants of affinity for CB I than is hydrogen-bonding capability (Pinto et
al., 1994). Venance et al. (1995) performed a limited SAR study to determine if changes in
the levels of saturation of anandamide would affect anandamide's ability to inhibit gapjunction conduction is striatal astrocyte cells. Analogs with 3, 2, 1 or O double bonds did
not produce a significant effect on gap-junction inhibition. These results concur with the
results presented in this dissertation that increasing the levels of saturation decreases
activity.

Finally, Welch et al. (1995) demonstrated that the fluorinated analog of

anandamide (fluorine substitution of the hydroxyl) was more potent than either anandamide
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or

Li9 -THC

in producing antinociception following i.t. administration in the mouse.

Results from this dissertation indicated that the fluorinated analog of anandamide had a
higher Ki in the absence of PMSF, like anandamide, but had affinity greater in the presence
of PMSF. It was similar in potency to anandamide in the spontaneous activity test, but was
l O times less potent than anandamide in producing antinociception following i. v.
administration. The difference in results from those of Welch et al. (1995) in regards to
antinociception might be due to the route of administration, i.v. versus i.t..
The behavioral and the binding data support the existence of a receptor whose
binding region possesses site(s) that accommodates both cannabinoid and anandamide
analogs. Molecular modeling approaches also support this hypothesis by demonstrating
that there is the possibility of a common pharmacophore (Martin et al., 1991). Specifically,
an anandamide conformation has been obtained using Sybyl molecular modeling software.
Thomas et al. (1996) performed a structure-activity analysis using several of the
anandamide analogs described in this dissertation to determine a molecular conformation of
anandamide that can be incorporated into a previously described model. A low energy
conformation of anandamide and the classical cannabinoids can be obtained with the
superposition of the oxygen of the carboxyamide with the pyran oxygen in Ll9 -THC, the
hydroxyl group of the ethanol with the phenolic hydroxyl group of Ll9 -THC, the five
terminal carbons and the pentyl side chain of Ll9-THC and the polyolefin loop overlaying
with the cannabinoid tricyclic ring (Thomas et al., 1996).
Several recent experiments have explored the link between the presence of
cannabinoid receptors in specific brain areas, including the striatum, globus pallidus,
substantia nigra pars reticulata and hippocampus, to the production of cannabinoid-induced
behaviors. Evaluating the effects of anandamide in the CNS is critical to understanding the
role of the proposed cannabinoid, or anandaminergic, neurochemical system. Intrastriatal
injection of WIN 55,212-2, CP 55,940 and anandamide induced turning behavior in mice
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(Souilhac et al., 1995). DA1 and DA2 antagonists or 6-hydroxydopamine lesions of the
striatum blocked WIN 55,2 12 - 2 and CP 55,940-induced turning behavior, suggesting
involvement of dopamine transmission in cannabinoid-induced turning. These results
support the role of CB I receptor mediation upon nigrostriatal function in the basal ganglia
It has been proposed that ti9 -THC produces catalepsy by enhancing GABAergic
transmission mediated by GABAA receptors located in the globus pallidus, a brain area
particularly rich in cannabinoid receptors. Wickens and Pertwee (1993) found that both
anandamide and ti9 -THC enhanced the ability of muscimol, a GABAA receptor agonist, to
induce catalepsy when the drugs were administered into the globus pallidus. The relevance
to humans that anandamide, when administered intrapallidally, also enhanced the ability of
a GABAA agonist to enhance catalepsy in rats is unknown. It also has been proposed that
cannabinoid receptors on striatonigral neuron terminals may regulate movement by
disinhibiting the activity of the substantia nigra pars reticulata neurons; this disinhibition
may occur by inhibiting the release of GABA into the substantia nigra pars reticulata (Miller
and Walker, 1995). These results suggest that a possible way by which endogenous
cannabinoids may regulate movement is by inhibiting striatonigral neurotransmission and
thereby disinhibiting the activity of the substantia nigra pars reticulata neurons.
Autoradiographic studies in rats have demonstrated that the cannabinoid receptor is located
on the axon terminals projecting to the globus pallidus and substantia nigra (Herkenham et
al., 1991b). These neurons are selectively lost in Huntington's disease. Glass et al.
(1993) used autoradiography to compare binding of [3 H]-CP 55,940 in the substantia nigra
of Huntington's disease and normal human brains.

In normal brains, cannabinoid

receptors are discreetly located within the substantia nigra pars reticulata. In contrast,
Huntington's disease brains have a massive loss (97%) of cannabinoid receptor binding in
the substantia nigra pars reticulata (Glass, Faull and Dragunow, 1993). These results
demonstrate that in the substantia nigra of the human brain, cannabinoid receptors are
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located on striatonigral terminals which degenerate in Huntington's disease. Cannabinoid
receptors are also present in the dentate gyrus and to a lesser extent in the entorhinal cortex.
Cannabinoids have been found to decrease paired-pulse facilitation of synaptic transmission
between perforant path axons and granule cells of the dentate gyrus (Kirby, Hampson and
Deadwyler, 1995). These results provide evidence making it likely that cannabinoids,
including endogenous compounds, play a role in controlling short-term plasticity of
perforant path synapses.
Cannabinoid receptors in the hippocampus have been implicated to produce
impairment of memory. Lichtman et al. (1995) studied the effects of cannabinoids on the
spatial memory in rats. Systemic administration of CP 55,940 and WIN 55,212-2
disrupted performance in the eight arm radial-maze, but anandamide did not. These results
suggest that systemic and intrahippocampal administration of cannabinoids acutely impair
working memory. Interestingly, anandamide was also inactive in the delayed nonmatching
to sample memory task in rats. The lack of effect of anandamide could be due to rapid
degradation or species specificity. Another possibility is that anandamide, or other
naturally occurring anandamides, might lack the memory-impairing effects of
cannabinoids. These compounds would be useful therapeutic agents if they possess
beneficial properties without impairing memory. Learning and memory processes result
from hippocampal long-term potentiation formation. Cannabinoids prevent LTP in rat
hippocampal slices. Anandamide also inhibits LTP (Collin et al., 1995; Terranova et al.,
1995).
One of the hindrances of cannabinoid research for many years was the lack of an
antagonist. The recent discovery of SR 141716A as the central cannabinoid antagonist
should greatly facilitate studying the physiological and psychological purpose of an
anandamide-based neurochemical system. If SR 141716A is the antagonist for the CB 1
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receptor, then it should localize to the same population of cannabinoid receptors in the
brain. Research has been conducted to assess the ability of SR 141716A to block the
effects of cannabinoids and anandarnide in both in vitro and in vivo systems. SR 141716A
antagonized the effects of cannabinoids in the mouse vas deferens and in inhibiting
adenylyl cyclase in cells transfected with the CB I receptor (Rinaldi-Carmona et al., 1994).
Inhibition of adenylyl cyclase in N1sTG2 mouse neuroblastoma cells by the anandamides
(22:4, n-6) and (20:3, n-6) was completely reversed by SR 141716A (Barg et al., 1995).
In vivo, SR 141716A antagonized cannabinoid-induced antinociception, hypothermia,
catalepsy and spontaneous activity depression (Rinaldi-Carmona et al., 1994). SR
141716A antagonized turning behavior in mice produced by intrastriatal administration of
WIN 55,212-2, CP 55,940 and anandamide (Souilhac et al., 1995). Anandamide's
inhibition of LTP in rat hippocampal slices was reversed by the cannabinoid antagonist
(Terranova et al., 1995). SR 141716A has been used to reveal whether CB1 receptor
blockade alters electrophysiological functioning of DA neurons in the substantia nigra pars
compacta, a target of the striato-nigral feedback system (Gueudet et al., 1995). Acutely,
SR 141716A increased SNC DA cell population response; after repeated administration,
SR 141716A decreased SNC DA cell population response. These results suggest that CB1
receptor blockade interrupts a cannabinoid endogenous tone controlling extrapyramidal
function.

Although SR 141716A blocks many of the effects of cannabinoids and

anandamides, one study demonstrated that SR 141716A did not block anandamide's
inhibition of gap-junction conductance in striatal astrocytes (Venance et al., 1995). This
result indicates that anandamide may modulate gap-junction permeability through a
mechanism distinct from the CB1 receptor. Thus, early research with SR 141716A
indicates that it antagonizes the effects of cannabinoids and anandarnide.
The purpose of the second part of this dissertation was to determine through
autoradiographic experiments if CP 55,940, anandamide and SR 141716A, three
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structurally diverse compounds, bound to the same populations of cannabinoid receptors.
Since CP 55, 940 is more potent than �9-THC, it has been used extensively to investigate
the effects of cannabinoids in both in vitro and in vivo experiments. It is important to
compare the binding patterns and densities of well-studied cannabinoids, such as CP
55,940, with anandamide, the endogenous ligand to the cannabinoid receptor. Differences
in receptor affinity and binding density between specific brain areas would provide
evidence that an endogenous ligand does not mimic all of the effects of THC and other
cannabinoids. If SR 141716A is truly an antagonist to the central cannabinoid receptor,
then it should bind to the CB I receptor in a similar manner to the binding distribution of CP
55,940 and anandamide. The use of SR 141716A as a cannabinoid antagonist is critical to
disseminating the function of an anandaminergic system in the central nervous system.
Therefore, establishing that SR 141716A is binding to CB I receptor in the same brain areas
as anandamide and CP 55, 940 is of great importance in this field. No quantitative
comparison has yet been made between CP 55,940, anandamide and SR 141716A.
Autoradiographic experiments were performed on rat brain slices to quantitate the
receptor affinity and binding density for anandamide, CP 55,940 and SR 141716A to the
central cannabinoid receptor. Measurements were made from 11 brain regions including
the entorhinal, occipital, parietal and frontal cortex, the lateral and medial caudate-putamen,
dentate gyms, CAI and CA3 regions of Ammon's horn, the substantia nigra pars reticulata
and the molecular layer of the cerebellum. These areas were selected since cannabinoids
have been shown to produce effects, such as memory disturbances, alterations in cognition
and movement, through probable interaction with these regions.
Comparisons were made between receptor affinities (Ki's) for each drug for the
selected brain regions. Statistical differences did not exist for anandamide's Ki's for the
brain areas, nor were there any statistical differences between Ki's for CP 55, 940 and SR
1 41716A. Thus, anandamide's affinity for the central cannabinoid receptor is the same
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across all of the rat brain examined. This is also true for SR 141716A and CP 55,940.
The next comparison was to determine if the three compounds were binding to the receptor
in the same manner. This was established through determination of the parallelism for a
representative curve from each region. All curves for anandamide and CP 55,940 were
parallel. All curves, except for the entorhinal cortex, for SR 141716A were parallel. The
physiological relevance of this difference remains to be established. The final comparison
was made by correlating the binding densities for anandamide and SR 141716A with the
binding densities of CP 55,940. High correlations existed, thus demonstrating that the
density in the cannabinoid receptors binding anandamide, CP 55,940 and SR 141716A
were very similar.
In summary, based upon an evaluation of receptor affinities for CP 55,940,
anandamide and SR 141716A and a comparison of receptor densities, the three compounds
appear to be binding to the same population of receptors in different brain areas. These
results provide both visual and quantitative results that the central cannabinoid receptor
binds all three compounds in a similar manner.
Even though the results in this dissertation provide no evidence for receptor
subtypes, it does not rule out the possibility that subtypes do exist. The technique of
autoradiography is not sensitive enough to detect small differences in receptor
subpopulations. Pharmacological differences between anandamide and other cannabinoids
could be due to interaction with a small number of as yet undiscovered subtypes.
Differences could also be metabolic in nature or to as yet undiscovered mechanisms.
Speculating on the physiological role of the anandaminergic system is difficult.
One cannot explain how a receptor can accommodate such a structurally diverse group of
compounds. Although ,19 -THC has been proposed to interact with the cannabinoid
receptor through a three point attachment, it is unknown which areas of anandamide, the
aminoalkylindoles and SR 141716A corresponds to these structural moieties in ,19 -THC.
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Future research will be essential in establishing the biological function of anandamide and
the family of anandamides.
In summary, this dissertation investigated anandamide's interaction with the central
cannabinoid receptor. Specific aims of this dissertation were met. Structural features of
anandamide important for anandamide's interaction with the cannabinoid receptor were
determined by in vitro and in vivo assays; anandamide was structurally modified to develop
compounds with higher binding affinity to the cannabinoid receptor; anandamide's binding
to the central cannabinoid receptor was characterized autoradiograpically in select brain
regions; and anandamide, CP 55,940 and the cannabinoid antagonist, SR 141716A were
shown to, respectively, bind to the same population of receptors in the same manner.
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